PRIORITISATION OF MEDICINES FOR IN-LICENSING BY THE MEDICINES PATENT POOL

ANNUAL REPORT 2024
Introduction

The mission of the Medicines Patent Pool (MPP) is to facilitate the development of-and increase access to, life-saving medicines and health technologies for low- and middle-income countries (LMICs) through public-health oriented voluntary licensing and technology transfer.

To do so, the first step for MPP is to identify suitable candidates for in-licensing using a prioritisation framework that is applied to assess products of potential interest in all health areas and all stages of clinical development. In line with MPP’s current mandate, products assessed include biotherapeutics and novel medical technologies.

This prioritisation process contributes to ensuring MPP focuses its efforts on medicines for which licensing could have the greatest public health impact.

Scope

MPP’s initial work began with infectious diseases including human immunodeficiency virus (HIV), viral hepatitis and tuberculosis (TB), and obtained licences that resulted in high public health impact.

In 2018, MPP’s mandate expanded to target patented medicines included in the World Health Organisation (WHO) Model List of Essential Medicines (EML) or with potential for future inclusion, which encompass a whole range of disease areas, including cancers, diabetes and cardiovascular diseases, and is exploring other areas of intervention, as relevant.

Additionally, MPP has been working on COVID-19 interventions since 2020. MPP’s new strategy for the 2023-2025 period embraces a disease agnostic approach, by which patented medicines for which an MPP intervention would potentially make a difference in public health, might be considered for prioritisation, regardless of the health area.

MPP’s work started with small molecules, and after conducting a feasibility study on expanding access to biotherapeutics in 2022, expanded its mandate on biologics. Moreover, given their ground-breaking potential impact, long-acting technologies and formulations designed to achieve longer exposure to medicines are considered for prioritisation since 2021, together with any relevant novel medical technologies for which an MPP intervention might generate positive impact for public health.

In line with MPP new strategy, candidate products in earlier stages of development are increasingly being considered for prioritisation. Therefore, MPP might consider for prioritisation candidates at any stage of development, from pre-clinical to marketed.

MPP prioritisation

MPP’s prioritisation process generates two lists of patented medicines for which expanded access in LMICs could provide significant health benefits over standards of care, and where voluntary licensing, through MPP could lead to substantial public health impact. These list guide MPP in-licensing efforts.

Two lists are generated:

PRIORITY LIST

MPP priority list of medicines includes patented medicines for which expanded access could provide significant health benefits over standards of care, and where voluntary licensing through MPP would lead to substantial public health impact.

WATCHLIST

Products in MPP watchlist are patented medicines for which expanded access could provide significant health benefits but for which supporting data are lacking and/or key challenges need to be addressed for expanded access through MPP licensing to provide significant benefits and lead to substantial public health impact.

Additionally, we include medicines in the watchlist when a potential added benefit might be obtained through an MPP licence, but where a full assessment is still ongoing.

Note: In the previous iteration of the prioritisation, we had two categories within the priority medicines list: list A and list B. List A included products approved by Stringent Regulatory Authorities (SRAs) and List B investigational products. We have simplified this classification into a single category : “priority list”.

The products classification into priority and watchlist medicines is evidence-based and guided by MPP’s prioritisation framework. Both lists are reassessed periodically based on new clinical evidence, changes to WHO recommendations and other recognised public health guidelines, changes in intellectual property landscape, evolution in access programmes, changes in prices or market forecasts, or any other relevant event. In order to guide products’ assessment, the framework addresses the following considerations, as guiding principles:

1. **Does the product address a public health need?**

   This question is assessed through the first pillar of the framework: the public health pillar, where the burden of the health condition is assessed, as well as the advantages of the candidate product over existing alternatives of care for this condition.

2. **Are there any access hurdles (anticipated or existing) for the product in low-and-middle-income countries?**

   This question is assessed through the second pillar: the access pillar. It includes access considerations on which MPP directly intervenes (e.g. intellectual property), as well as additional access considerations which may be important in the treatment cascade (e.g. access to diagnostics).

3. **What would be the effect of MPP intervention on access?**

   This question elaborates on both public health and access pillars, and it ensures that candidate products are prioritised where an MPP intervention could yield the greatest impact.

   By addressing these questions, MPP collects insights about public health and access dimensions of the products assessed, as well as insights to assess the potential impact of an MPP intervention.

The framework is structured into seven pillars as shown in the next page. These are the clinical relevance of the candidate, the burden of disease that is targeted, the product’s intellectual property landscape, the service delivery enablers to be considered for the product implementation, regulatory aspects, manufacturing requirements and market prospects.

Within each pillar, several criteria are considered. These are further broken down into subcriteria. For reading ease, the graphic only comprises the pillars and criteria. The detailed sub-criteria are presented in the annex at the end of this report.
SERVICE DELIVERY ENABLERS
- Diagnostic
- Companion drugs
- Health system requirements

DISEASE BURDEN
- Prevalence & incidence
- Treatment options
- Disease severity
- Epidemic risk

INTELLECTUAL PROPERTY LANDSCAPE
- Years to patent expiry
- Geographical coverage
- Secondary patents
- Multiple patent owners

CLINICAL RELEVANCE
- Safety & efficacy
- Posology & method of administration
- Cross-disease impact

REGULATORY
- Regulatory pathway
- Regulatory cost & complexities
- Probability of biowaiver/clinical trial waiver

MARKET
- Affordability & availability of the candidate
- Commercial potential for generic manufacturers
- Impact

MANUFACTURING
- Manufacturing simplicity
- Presentation & storage
MPP prioritised and watchlist products 2024

**HIV**
- lenacapavir (Gilead)
- cabotegravir & rilpivirine (WIV & Janssen)
- doravirine (MSD)
- islatravir (Merck)
- broadly neutralising antibodies for HIV post-natal prophylaxis (Multiple patent holders)

**TUBERCULOSIS**
- quabodepistat (Otsuka)
- BTZ-043 (Univ. of Munich & DZIF)
- delpazolid (LegoChem BioSciences)
- ganfeborole (GSK)
- macozinone (EPFL)
- sudapyridine (Shanghai Jiatan Biotech)

**VIRAL HEPATITIS**
- bulevirtide (Gilead)
- gepotidacin (GSK)

**OTHER INFECTIONOUS DISEASES**
- baloxavir marboxil (Roche)

**DIABETES, CARDIOVASCULAR & METABOLIC DISORDERS**
- Incretin-based therapies (Multiple patent holders)
- Cardiovascular fixed-dose combination therapies (Multiple patent holders)

**ONCOLOGY**
- LUNG CANCER
  - aumolertinib (Revolution Medicines)
  - osimertinib (Astrazeneca)
  - adagrasib (Mirati)
  - lazertinib (Janssen)
  - sotorasib (Amgen)

- BREAST CANCER
  - abemaciclib (Eli Lilly)
  - ribociclib (Novartis)
  - trastuzumab SQ (Roche)
  - trastuzumab

- CHRONIC LYMPHOCYTIC LEUKAEMIA
  - ibrutinib (Janssen)
  - zanubrutinib (Beigene)

- PROSTATE CANCER
  - apalutamide (Janssen)
  - darolutamide (Bayer)

- MULTIPLE CANCER INDICATIONS
  - immune checkpoint inhibitors
    - pembrolizumab (MSD)
    - oral paclitaxel / encequidar (Astellas)
  - Multiple patent holders

**PANDEMIC & EPIDEMIC THREATS**
- geopotidacin (GSK)
- bulovertid (Gilead)
- islatravir (ViiV & Janssen)
- baloxavir marboxil (Roche)
- cabotegravir & rilpivirine (WIV & Janssen)

**RESPIRATORY SYNCYTIAL VIRUS**
- nirsevimab (Astrazeneca/Sanofi)
- clesrovimab (MSD)

**SICKLE CELL DISEASE**
- voxelotor (Pfizer)

**CYSTIC FIBROSIS**
- elexacaftor/tezacaftor/ivacaftor (Vertex)

**CHILDHOOD ONSET DISEASES**
- nirsevimab (Astrazeneca/Sanofi)
- clesrovimab (MSD)

**PRIORITY LIST**
- MARCH 2024
What is new in 2024 list?

The following graph and table summarise the main changes in the list compared to 2023 prioritisation. There were additions, changes in classification, and products that have been de-prioritised and removed from the list.

Additions and changes

It should be also noted that MPP does not include in its prioritisation medicines for which it has already obtained licences*.

*MPP licences
### Removals

<table>
<thead>
<tr>
<th>Health Area</th>
<th>Indication</th>
<th>Product/class</th>
<th>Originator</th>
<th>Rationale for removal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HIV</strong></td>
<td></td>
<td>ultra-long acting injectable formulation of antiretrovirals (ARVs)</td>
<td>University of North Carolina at Chapel Hill</td>
<td>Patent coverage</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GSK3640254</td>
<td>ViiV Healthcare</td>
<td>Development seems halted</td>
</tr>
<tr>
<td><strong>TUBERCULOSIS</strong></td>
<td></td>
<td>bedaquiline</td>
<td>Janssen</td>
<td>Licenced out</td>
</tr>
<tr>
<td></td>
<td></td>
<td>telacebec</td>
<td>Qurient Therapeutics</td>
<td>Licenced out</td>
</tr>
<tr>
<td></td>
<td></td>
<td>fobrepodacin</td>
<td>Spero Therapeutics</td>
<td>Indication too narrow</td>
</tr>
<tr>
<td><strong>MATERNAL HEALTH</strong></td>
<td>PREVENTION OF POST-PARTUM HAEMORRHAGE</td>
<td>heat-stable carbetocin</td>
<td>Ferring Pharmaceuticals</td>
<td>MPP agreement</td>
</tr>
<tr>
<td><strong>ONCOLOGY</strong></td>
<td>LUNG CANCER</td>
<td>furmonertinib</td>
<td>Allist Pharmaceuticals</td>
<td>Impending patent expiry</td>
</tr>
<tr>
<td></td>
<td>PROSTATE CANCER</td>
<td>enzalutamide</td>
<td>Pfizer/Astellas</td>
<td>Patent coverage</td>
</tr>
<tr>
<td></td>
<td>MULTIPLE CANCER INDICATIONS</td>
<td>oral docetaxel</td>
<td>Athenex</td>
<td>Development seems halted</td>
</tr>
<tr>
<td><strong>DIABETES, CARDIOVASCULAR AND METABOLIC DISORDERS</strong></td>
<td></td>
<td>empagliflozin</td>
<td>Boehringer Ingelheim</td>
<td>Class effect of SGLT2i</td>
</tr>
<tr>
<td></td>
<td></td>
<td>canagliflozin</td>
<td>Janssen</td>
<td>Class effect of SGLT2i</td>
</tr>
</tbody>
</table>
Overview of products by health area
There are 39 million people living with human immunodeficiency viruses (HIV) worldwide, but only 29.8 million currently receive antiretroviral therapy (ART). HIV paediatric care is improving, but still only one in two children living with the virus has access to treatment.

HIV prevention is also key to tackle the transmission of the disease. Although Pre-Exposure Prophylaxis (PrEP) has proven efficient in preventing HIV infection, its uptake is still slow. Affordable, effective HIV medicines are imperative, especially for people living with HIV (PLHIV) in low- and middle-income countries (LMICs) where HIV is most prevalent.

Medicines must also be available in the right formulations. Fixed-dose combinations and long-acting formulations increase adherence. Specially formulated treatments for children, appropriate for different ages and weights, improve care.

Since 2010, we have worked with leading HIV drug manufacturers, governments, international organisations, civil society, and affected communities to improve access to World Health Organization prioritised and recommended medicines for people living with HIV in LMICs. We have also worked to increase access to HIV prevention tools and support the diversification of prevention options. In 2022, MPP signed a voluntary licensing agreement with ViiV Healthcare for cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP). This is an important step in accelerating affordable and equitable access to long-acting PrEP in over 90 countries.

Given the current landscape in the HIV space, MPP has identified one medicine as priority and has included two medicines, one regimen and class in the watchlist.

Relevant changes in the 2023 MPP prioritisation report compared to the previous year are:

- addition of monoclonal antibodies for HIV post-natal prophylaxis in the watchlist,
- removal of ultra-long-acting injectable formulations for ARVs from the priority list, because of lack of patent coverage,
- removal of the three monthly dual vaginal ring for HIV PrEP and prevention of unintended pregnancy, because of lack of progress in development,
- removal of GSK3640254 from the watchlist because its development was stopped.

**Lenacapavir**

Lenacapavir was first included as a priority for MPP in 2022 and it continues to be a priority because it has a new mechanism of action and its half-life allows for a 6 months dosing interval. Lenacapavir will likely be an important product in HIV prevention and/or treatment (in combination with other medicines). The clinical programs continue to show an overall favourable efficacy and safety profile. It is being investigated as a standalone injectable for HIV PrEP (6 monthly) and for treatment in combination with islatravir as weekly treatment regimen. Furthermore, lenacapavir has been prioritised by the Conference on Antiretroviral Drug Optimization (CADO) and is present in the Paediatric Antiretroviral Drug Optimization (PADO) watchlist.
Cabotegravir (CAB) is the only approved integrase strand transfer inhibitor (INSTI) in combination with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) constituting a fully long-acting treatment for HIV.

This combination regimen is indicated in virologically suppressed adults with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

Injectable cabotegravir and rilpivirine regimen for HIV treatment is not currently listed in WHO guidelines for the treatment of HIV.

This regimen could support treatment adherence and sustain virological suppression in comparison with daily oral treatments. Recent data presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI2024) indicated that people living with HIV with adherence challenges and receiving long-acting injectable cabotegravir and rilpivirine (CAB/RPV) had further reductions in their viral loads than with oral antiretroviral treatment (ART).

Additionally, recent data from the CARES study showed that in sub-Saharan Africa, switching to LA CAB/RPV vs. continuing oral ART yielded high rates of HIV-1 RNA suppression at week 48 (LA CAB/RPV was non-inferior to oral ART). This study represents an initial success of such combination in LMIC settings.

There might be still some challenges that could prevent this 2-drugs regimen from being widely implemented in LMICs. Eventual rilpivirine resistance could challenge future use of the NNRTI class drugs. Additionally, rilpivirine (not cabotegravir) requires a cold chain and presents some safety issues including hepatic adverse effect.

For people living with hepatitis B, switching from a tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)-containing regimen (such as oral tenofovir/lamivudine/dolutegravir (TLD)) to CAB/RPV would deprive these individuals from the HBV suppressive action of TDF or TAF. Finally there are some drug-drug interactions with tuberculosis treatment regimens including rifampicin and rifabutin.

Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It is being investigated for HIV treatment in combination with islatravir as once daily oral treatment and it has the potential to be an alternative treatment, including PLHIV experiencing weight-gain.

Additionally, some of its development program is focused on infants and children. However, the evidence of clinical benefits over the standard of care is unclear.

Islatravir is the first drug of a new class called nucleoside reverse transcriptase translocation inhibitors (NRTTIs). Its new mechanism of action and its long-acting properties have the potential to make it an important product in HIV treatment. After a period of pause in clinical development involving islatravir due to safety concerns, Merck has resumed some islatravir’s development programs while monitoring closely its safety.

Furthermore, islatravir is one of the most promising drugs studied in combination with lenacapavir for oral weekly treatment.

These laboratory-made proteins emulate the immune system’s ability to counteract harmful pathogens, including HIV.

Although still in the early stages of development, broadly-neutralising antibodies demonstrate significant potential for use in post-natal prophylaxis (PNP) against HIV, due to their favourable safety profile and the convenience they may offer through a single administration via intramuscular injection. Despite the potential benefits, crucial clinical data on the efficacy of monoclonal antibodies for PNP remain lacking. Specifically, there is a notable gap in understanding whether a single monoclonal antibody could suffice for prevention. If multiple mAbs are necessary, the cost could become a challenge, especially when compared to cheaper small molecules.
An estimated global total of 10.6 million people fell ill with tuberculosis (TB) in 2021, most in low- and middle-income countries. TB is the leading cause of death for people with HIV and a major contributor to antimicrobial resistance. In 2021, 1.6 million people died from TB, including 187,000 people with HIV.

Globally, there were an estimated 450,000 incident cases of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) in 2021. The World Health Organization’s post-2015 Global TB Strategy sets ambitious targets at reducing TB deaths by 95% between 2015 and 2035, and to end TB. To meet these targets, better therapies to treat TB are urgently needed, particularly for MDR-TB.

Since 2020, PAN-TB, Project to Accelerate New Treatments for Tuberculosis (both drug sensitive (DS-TB) and multidrug-resistant TB) aims at developing new drug regimens to transform the care of patients with tuberculosis. We work to improve access to new treatments for MDR-TB and DS-TB.

We also facilitate the development of new regimens by licensing TB drugs that are still under development. In early 2017, MPP signed its first agreement with the Johns Hopkins University. This agreement was signed to facilitate the clinical development of sutezolid, a promising investigational treatment for tuberculosis. It was followed by a second agreement with Pfizer in October 2019 to access Pfizer’s preclinical, phase I and phase IIa clinical study data and results on sutezolid. The agreement’s aim was to further study, develop and make available this potential important component of new TB regimens.

Given the current situation in the TB space, MPP has identified one medicine as a priority and has included five in the watchlist. Relevant change in the 2023 MPP prioritisation report compared to the previous year are the removal of fobrepodacin and telacebec from the watchlist. This removal is justified by the fact that fobrepodacin has been studied mainly for non-tuberculous mycobacterial disease and telacebec has been licensed to TB alliance, a public health organisation already committed to LMICs access.
Quabodepistat (OPC-167832) is a molecule with a new mechanism of action that has potent antituberculosis activity and a favourable safety profile. It is now studied as part of a new, promising, TB regimen under the Project to Accelerate New Treatments for Tuberculosis (PAN-TB) program, in combination with delamanid, bedaquiline, and sutezolid (DBOS) or in combination with pretomanid, bedaquiline and sutezolid (PBOS).

BTZ-043 is an investigational agent, active against all tested Mycobacterium tuberculosis strains, including multidrug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB) clinical isolates. The clinical data on BTZ-043 are still immature and therefore the drug candidate remains on the watchlist.

Delpazolid is an investigational antitubercular agent. It is being studied in combination with delamanid and bedaquiline. As the clinical data are still immature, the drug candidate remains in the watchlist.

Ganfeborole (GSK3036656) is an investigational agent, demonstrating early bactericidal activity with a low, once-daily oral dose after 14 days of treatment in participants with drug-susceptible pulmonary tuberculosis. The clinical data on GSK3036656 is still immature and therefore the drug candidate remains in the watchlist.

Macozinone (PBTZ-169) is a tuberculosis drug candidate that has demonstrated high potency against drug-susceptible and drug resistant Mycobacterium tuberculosis in pre-clinical studies. Macozinone has additive effects with many tuberculosis therapeutic agents, both marketed and in development, and has synergic effects with bedaquiline and clofazimine in preclinical models. Clinical data on macozinone are still immature.

Sudapyridine (WX-081) is a bedaquiline analogue, displaying antimycobacterial activity and low toxicity. Clinical data on sudapyridine are still immature.
Of the five types of hepatitis infections, hepatitis B and C (HBV and HCV) cause most of the disease and deaths. 354 million people globally live with a hepatitis B or C infection. Hepatitis causes liver damage and cancer. Globally, viral hepatitis causes approximately 1.34 million deaths annually, with 66% of the deaths attributed to HBV infection. HCV can be cured; however, only 21% of people living with hepatitis C infection are diagnosed and only 13% have received curative treatment.

MPP works with a wide range of partners including originator and generic companies, governments, WHO, civil society and communities, procurement agencies, and others to expand and accelerate the development and distribution of these new treatments that can eliminate the virus through a short course of oral therapy in LMICs with a high HCV burden.

Among the other types of hepatitis infections, it is estimated that hepatitis D virus (HDV) affects nearly 5% of people globally who have a chronic infection with HBV, and that HDV co-infection could explain about one in five cases of liver disease and liver cancer in people with HBV infection. Patients with HDV-induced cirrhosis are at an increased risk of hepatocellular carcinoma (HCC). It is still unknown which fraction of the HBV-associated mortality involves disease complicated by HDV infection, and quantitative data on the contribution of HDV infection on the outcome of HBV infection are largely lacking.

Given the current pipeline in the viral hepatitis space, MPP has not identified a priority product and has included one medicine in the watchlist for Hepatitis D.

---

**Bulevirtide**

Bulevirtide was recently conditionally approved by the European Medicines Agency (EMA) and is today the only specific treatment for hepatitis delta. The treatment's duration and the necessity of a daily subcutaneous injection may present some challenges in LMICs. Additionally, its safety and efficacy are still under evaluation and therefore bulevirtide has been included in the watchlist.
MPP started its work by focusing on infectious diseases, notably HIV, aiming to expand access to life-saving medications. Supported by its successes in HIV, MPP expanded its scope to include TB and hepatitis, recognizing the significant burden these diseases impose on global health and particularly in LMICs due to their high prevalence. Other infectious diseases, while not commanding the level of attention to HIV, TB, or hepatitis, still represent significant public health burden in LMICs.

An example of one such pressing issue is antimicrobial resistance and in particular, antibiotic resistance, where the development of innovative antibiotics is crucial to mitigate the rising threat posed by resistant pathogens. MPP’s commitment to identify promising new medicines for infectious diseases caused by pathogens which have developed resistance against available therapies, is balanced with stewardship efforts to avoid development of resistance to new antimicrobials. This is an area in which MPP has already undertaken work in the context of its TB activities, and it will continue to support ongoing efforts to combat antimicrobial resistance.

In this context, MPP has included one medicine in the watchlist for Uncomplicated Urinary Tract Infections (UUTI) and of Uncomplicated Urogenital Gonorrhoea (UUG).

**Gepotidacin**

Gepotidacin is an investigational first-in-class oral antibiotic for treatment of uncomplicated urinary tract infections and of Uncomplicated Urogenital Gonorrhoea (UUG). Gepotidacin is active against most strains of target uropathogens, such as *E.coli* and *Staphylococcus saprophyticus*, including isolates resistant to current antibiotics. Furthermore, due to gepotidacin’s mechanism of action, blocking bacterial DNA replication by inhibiting two vital enzymes, mutations in both enzymes are needed to significantly affect susceptibility to gepotidacin. This gives hope that this drug will stay effective as resistance would be harder to develop. A recent press release from GSK announced that the EAGLE-1 trial met its primary efficacy endpoint, with gepotidacin (oral, two doses of 3,000mg) demonstrating non-inferiority to intramuscular (IM) ceftriaxone (500mg) plus oral azithromycin (1,000mg), a leading combination treatment regimen for gonorrhoea.
Epidemics are an unexpected, often sudden, increase of a specific illness within a community or region. Pandemics are when an epidemic occurs worldwide, crossing international borders and affecting a large number of people. A number of communicable diseases can be significant health threats at the local, regional and global level and lead to epidemics or pandemics. Epidemics and pandemics can be prevented and mitigated through a range of measures, such as good hygiene, social distancing, medicines and vaccination. Pandemics pose a significant threat to global health security. By actively engaging in pandemic preparedness, MPP contributes to the resilience of healthcare systems and helps mitigate the impact of future health crises. MPP works with innovators and pharmaceutical companies to expedite the development and manufacturing of medical countermeasures. By facilitating intellectual property licensing and technology transfer, MPP can support the production of these life-saving tools in LMICs and contribute to ensuring that pandemic-related products are accessible to governments and healthcare systems, especially in low- and middle-income countries, in an equitable manner.

Among the epidemic threats, MPP has been monitoring the influenza space. Seasonal influenza is an acute respiratory infection caused by influenza viruses which circulate in all parts of the world. It represents a year-round disease burden. It causes illnesses that range in severity and sometimes lead to hospitalization and death. Worldwide, influenza epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 290,000 to 650,000 respiratory deaths annually. Given its potential impact on eventual influenza pandemics, MPP has added baloxavir marboxil as a priority product for in-licensing.

Given the current situation in the pandemic and epidemic threats, MPP has identified one medicine as a priority for influenza. The relevant change in this report compared to the previous MPP prioritisation is the addition of baloxavir marboxil for influenza.

Baloxavir marboxil, an oral one-dose, one-time treatment for influenza, could serve, in addition to its use in seasonal influenza, as a valuable tool in pandemic preparedness in the event of a novel and highly virulent influenza strain.

As a drug in a new class of antiviral treatment for influenza, it could provide an additional layer of defence and an option against viruses resistant to existing antivirals.
In 2023, MPP joined forces with Ferring Pharmaceuticals through a formal agreement to broaden access to heat-stable carbetocin (HSC). This innovative drug is vital for preventing post-partum haemorrhage, a serious condition that leads to the death of approximately 66,500 women annually in low- and middle-income countries. HSC, which has been recognised as essential by the EML core list since 2019, matches oxytocin in effectiveness and safety, and crucially, does not require refrigeration. This is particularly beneficial in regions with limited resources.

Currently, we are not specifically prioritising medicines within the maternal health area. However, it is important to note that our prioritization process is dynamic and conducted on a rolling basis. New candidates for in-licensing could be considered and added to our priority or watch lists at any time, should they meet our framework criteria.

Non-communicable diseases (NCDs) are the leading cause of death among women, accounting for three-quarters of female deaths each year. Breast and cervical cancers are the most diagnosed and deadly cancers for women globally, with a significant number of these deaths occurring in underprivileged areas. To address these challenges, MPP is focusing on specific treatments, including the immune checkpoint inhibitor class and five other products that are key in combating breast and cervical cancers. This targeted approach is part of MPP’s commitment to improving healthcare outcomes for women around the world.
Across most disease areas in which MPP has been working on, access to appropriate medicines for children lags behind that for adults, and in many cases important medicines are not available in formulations that can be taken easily by young children.

Since its inception, MPP has prioritised working with manufacturers on bringing quality-assured paediatric formulations to market, including accelerating their development and facilitating uptake. This contribution has increasingly taken place in partnership with other key stakeholders in the paediatric field.

Moving forward, MPP will continue to place particular focus on addressing the needs of children across all disease areas in which it operates. Its contribution in paediatrics will be framed in alignment with the Global Accelerator for Paediatric Formulations Network (GAP-f) a WHO network of which MPP is a founding member, to ensure that the most-needed, optimal paediatric formulations are prioritised, developed, and made available to children swiftly and efficiently.

This chapter provides a summary of MPP priorities and watchlist in the field of childhood onset diseases. The relevant changes in this report compared to the previous MPP prioritisation are: The addition of nirsevimab to the priority list and of clesrovimab to the watchlist for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease, and the addition of elexacaftor/tezacaftor/ivacaftor on the watchlist for the management of cystic fibrosis.

**RESPIRATORY SYNCYTIAL VIRUS**

Respiratory syncytial virus (RSV) is a virus that causes acute respiratory infection in individuals of all age groups.

While most infants and young children experience mild, cold-like symptoms, some infants, especially with their first infection, develop lower respiratory tract disease such as pneumonia and bronchiolitis (swelling of the small airway passages in the lungs), that often leads to an emergency department or physician office visit.

Infants have the highest incidence of severe disease, peaking at 1 to 3 months of age. Premature infants, and those with chronic lung disease of prematurity or significant congenital heart disease, are at highest risk for severe RSV disease. RSV caused an estimated 101,400 deaths in children under five in 2019.

**nirsevimab** AstraZeneca/Sanofi

Nirsevimab is a monoclonal antibody with activity against RSV. Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens such as viruses. One dose of nirsevimab administered to infants as a single intramuscular injection prior to, or during RSV season, may provide protection during the RSV season.

**clesrovimab** MSD

Clesrovimab is a monoclonal antibody with activity against Respiratory Syncytial Virus (RSV). Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. Although the product is still in development, one dose of clesrovimab administered to infants as a single intramuscular injection may provide protection against RSV.
Cystic fibrosis is a rare, progressive, life-threatening disease, caused by mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene that results in the formation of thick mucus that builds up in the lungs, digestive tract, and other parts of the body. It leads to severe respiratory and digestive problems as well as other complications such as infections and diabetes.

There is no cure and people with cystic fibrosis receive daily treatments depending on the severity of their symptoms. There are no global annual deaths estimates for cystic fibrosis and related life expectancy, but it is generally assumed that in the absence of CFTR modulators, the median life expectancy for cystic fibrosis would be around 24.5 years (compared to 46 in presence of CFTR).

The combination of the active substances elexacaftor, ivacaftor and tezacaftor is the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation.

It is approved for use in patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population.

Voxelotor is a haemoglobin oxygen-affinity modulator approved by the United States Food and Drug Administration (USFDA) in 2019 for the treatment of sickle cell disease.

Voxelotor has a different mode of action from that of conventional standard of care therapies, which makes it relevant as additional treatment or in case of intolerance.
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Among the prevalent cancer types, breast, lung, colon and rectum, prostate, stomach, liver, cervix uteri and skin cancers stood out as the most frequently encountered. Many cancers can be cured if detected early and treated effectively.

Many health systems in low- and middle-income countries remain ill-equipped to cope with this growing health crisis. Consequently, a significant portion of cancer patients worldwide continues to face significant barriers to accessing timely and high-quality diagnosis and treatment.

This chapter provides a summary of MPP priorities and watchlist respectively, in the field of oncology. Relevant changes in the 2024 MPP prioritisation report compared to the previous year are:

- addition of pembrolizumab as a priority within the class of the immune checkpoint inhibitors;
- addition of subcutaneous trastuzumab to the priority list;
- removal of furmonertinib and enzalutamide from the watchlist due to patent expiry and patent coverage respectively;
- removal of oral docetaxel + encequidar from the watchlist as its development seems halted.
LUNG CANCER

Lung cancer arises from the rapid and unregulated proliferation of abnormal cells in the lungs, posing a significant threat to health and carrying a high risk of fatality.

The two most common forms of lung cancer are: non-small cell lung carcinoma (NSCLC), which is prevalent and tends to develop at a gradual pace, and small cell lung carcinoma (SCLC), which is rarer but usually exhibits a rapid growth rate. In low- and middle-income countries (LMICs), there were 1.2 million incident cases of non-small cell lung cancer (NSCLC) in 2020.

Unfortunately, around 70% of NSCLC cases are diagnosed in advanced stages, such as locally advanced or metastatic.

Aumolertinib

Aumolertinib is a 3rd generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI), that has demonstrated significant benefits compared to standard first-line treatments of 1st and 2nd generations in the WHO Essential Medicines List for the treatment of non-small cell lung cancer.

Aumolertinib is under review for approval by the European Medicines Agency (EMA).

Osimertinib

Osimertinib is a 3rd generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) approved by the Food and Drug Association and the European Medicines Agency.

It has demonstrated significant benefits compared to standard first-line treatments of 1st and 2nd generations in the WHO Essential Medicines List (EML) for the treatment of non-small cell lung cancer.

The EML committee called on MPP to explore licensing opportunities for osimertinib.

Adagrasib

Adagrasib is an oral Kirsten Rat Sarcoma Virus (KRAS) inhibitor that received approval by the Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) in 2022 and showcases durable clinical benefits in patients.

Sotorasib

Sotorasib is an oral Kirsten Rat Sarcoma Virus (KRAS) inhibitor, that received accelerated approval by the Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) in 2021. A recent study showed that sotorasib offered significant benefits compared to the standard intravenous treatment.

Lazertinib

Lazertinib is an investigational 3rd generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI), presenting superiority over the 1st generation of EGFR TKI. Lazertinib has a strong potential as alternative option for lung cancer treatment.
Breast cancer is the most commonly occurring cancer in women. In 2022, there were over 2.29 million new cases of breast cancer in women, leading to an estimated 669,418 deaths, many of which disproportionately occurred in low-resource settings.

There are four main female breast cancer subtypes, including the following in order of prevalence: HR+/HER2-, HR-/HER2-, HR+/HER2+, HR-/HER2+.

- **HR** stands for hormone receptor.
- **HR+** means that tumour cells have receptors for the hormones estrogen or progesterone, which can promote the growth of HR+ tumours.
- **HER2** stands for human epidermal growth factor receptor 2.
- **HER2+** means that tumour cells make high levels of a protein called HER2/neu, which has been shown to be associated with certain aggressive types of breast cancer.

**Abemaciclib** is an oral cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, approved by the Food and Drug Administration for the treatment of HR+/HER2- advanced breast cancer, recommended as the preferred option in the treatment of advanced breast cancer. CDK 4/6 inhibitors are the recommended preferred option in the treatment of advanced breast cancer.

The Essential Medicines List (EML) expert committee recognised its potential for future inclusion and recommended to MPP to explore licensing opportunities.

Abemaciclib has a similar safety profile to ribociclib but with a different dosing regimen, making it an alternative of interest.

**Ribociclib** is an oral Cyclin-Dependent Kinase 4 and 6 (CDK 4/6) inhibitor, approved by the USFDA for the treatment of HR+/HER2- advanced breast cancer.

The Essential Medicines List expert committee recognised its potential for future inclusion and recommended to MPP to explore licensing opportunities.

**Trastuzumab SQ** is a monoclonal antibody approved by the USFDA in 2019 for the treatment of HER2+ over-expressing breast cancer. It is the same monoclonal antibody as intravenous trastuzumab with the advantage of being easier and more rapid to administer.
**CHRONIC LYMPHOCYTIC LEUKAEMIA**

Chronic Lymphocytic Leukaemia (CLL) is the most common form of leukaemia, accounting for 25% to 30% of all leukaemia cases in Western countries. In 2019, CLL resulted in 44,612 deaths worldwide. Regarding incidence rates in 2019, CLL affected 1.34 individuals per 100,000 in the global population, with rates of 1.13 in high-income countries, 0.45 in middle-income countries, and 0.28 in low-income countries. Central Sub-Saharan Africa is experiencing the fastest growth in disease rates, with deaths increasing by 2.8% each year and the impact on daily life growing by 2.66% annually.

CLL predominantly occurs in older individuals, peaking in the elderly population, with a median age at diagnosis of 71 years in Europe. Furthermore, the incidence of CLL is approximately twice as high in males compared to females.

Ibrutinib is a Bruton’s Tyrosine Kinase Inhibitor (BTKi) approved by the Food and Drug Administration in 2013 and added to the complimentary list of the Essential Medicines List for the treatment of CLL. Ibrutinib demonstrated major benefits compared to chemo-immunotherapy. The Essential Medicines List expert committee recommended to MPP to explore licensing opportunities.

Zanubrutinib is a Bruton’s Tyrosine Kinase Inhibitor (BTKi) approved by the USFDA in 2023 for the treatment of CLL. Recognising the emerging important role of BTKi as a therapeutic class in the treatment of CLL, the EML Committee advised that it would consider an application for zanubrutinib as therapeutic alternative for inclusion and recommended to MPP to explore it for licensing.

**PROSTATE CANCER**

Prostate cancer made up 7.3% of all new cancer cases in 2022, accounting for 14.2% of all new male cancer diagnoses.

Notably, cancer incidence rates have been on the rise in various sub-Saharan African populations. Men of African descent face nearly double the risk of being diagnosed with prostate cancer before the age of 45 compared to Caucasian men.

Apalutamide is a 2nd generation androgen receptor antagonist approved by the USFDA in 2018. As a class of drugs, 2nd generation androgen receptor antagonists improve overall survival in prostate cancer patients. Apalutamide is a strong potential alternative candidate.

Darolutamide is a 2nd generation androgen receptor antagonist approved by USFDA in 2019. As a class of drugs, 2nd generation androgen receptor antagonists improve overall survival in prostate cancer patients. Darolutamide is a strong potential alternative candidate.
Immune checkpoint inhibitors (ICIs) represent a revolutionary advance in the field of oncology, offering a new horizon in the treatment of cancer by immunotherapy. These monoclonal antibodies block proteins that would prevent the immune system from attacking cancer cells. The best-known representatives of this class are PD-1 and PD-L1 inhibitors. The versatility of ICIs has led to their approval for the treatment of a wide range of cancers, and the pipeline of new ICIs is robust and promising.

The importance of ICIs in this context is underlined by the World Health Organization’s (WHO) Essential Medicines List (EML) Committee, which has recognised their importance by including certain ICIs on the list of essential medicines for the treatment of cutaneous melanoma. This reflects their therapeutic value and their potential for wider application. In particular, ICIs have shown that they can play an essential role in the fight against certain types of breast and cervical cancer, which remain the most diagnosed and deadliest forms of cancer for women in low- and lower-middle-income countries (LMICs).

The WHO EML Committee recommended continuing to work on strategies to improve the affordability of these medicines, and also suggested considering licensing to MPP, as our support for technology transfer could contribute to successful implementation by reducing the development time and costs of biosimilar versions for use in low- and middle-income countries. In line with these efforts, MPP has strategically prioritised ICIs as a class, with pembrolizumab presented as an example/priority.

Pembrolizumab as a single agent reduces the risk of death in non-small cell lung cancer patients by 40%, significantly extending survival by more than a year with fewer side effects compared to traditional chemotherapy. Pembrolizumab is also indicated against several other cancers.

The intravenous formulation of paclitaxel was added to the EML in 2011 and used in the treatment protocols for many cancers. Pending confirmation of its safety and efficacy, this new mode of oral administration, currently under development, could be particularly promising for LMIC settings, and therefore have been included in the watchlist.
Cardiovascular diseases (CVDs) stand as the leading global cause of death, accounting for 32% of all deaths in 2019, with an estimated 17.9 million lives lost. Over three-quarters of CVD deaths occur in low- and middle-income countries. These diseases were responsible for 38% of the 17 million premature deaths (those under 70 years old) attributed to noncommunicable diseases in 2019. Early detection of cardiovascular disease is paramount to initiate timely management through counselling and medication. Despite high-quality scientific evidence of the benefits of different classes of drugs in preventing and controlling cardiovascular disease, their current use remains low.

Currently, 537 million adults (10.5% of the global population) are grappling with diabetes. Projections indicate that this number will climb to 643 million by 2030. Approximately 240 million individuals worldwide live with undiagnosed diabetes, meaning nearly one out of every two adults is oblivious to their condition. Notably, 90% of these undiagnosed cases are concentrated in low- and middle-income countries (LMICs). Type 1 diabetes afflicts over 1.2 million children and adolescents, with 54% of them under the age of 15. Type 2 diabetes is the most common type of diabetes, accounting for over 90% of all diabetes worldwide. Globally, the prevalence of type 2 diabetes is high and rising across all regions and has also become a concern in children and young people as a result of an increasing prevalence of obesity.

This chapter provides a summary of MPP priorities and watchlist in the diabetes, cardiovascular and metabolic disorders field. No medicine was identified as priority, but two classes of products are now included in the priority list: the incretin-based therapies and in the watchlist: the cardiovascular fixed-dose combination therapies.

In the 2024 report, empagliflozin and canagliflozin were removed from the priority list due to the expiration of dapagliflozin's patent and the inclusion of this drug class with a square-box indication in the EML.

**DIABETES, CARDIOVASCULAR & METABOLIC DISORDERS**

The incretin hormones are gut hormones that amplify nutrient-induced insulin secretion in response to meal intake. Incretin peptides, principally Glucagon-like Peptide-1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP), regulate islet hormone secretion, glucose concentrations, lipid metabolism, gut motility, appetite and body weight, and immune function, providing a scientific basis for utilising incretin-based therapies in the treatment of type 2 diabetes (T2DM).

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have proven efficacy in T2DM management as they effectively reduce glycaemia and weight while posing a low risk of hypoglycaemia. Some GLP-1 RAs also have documented beneficial effects on the cardiovascular system, chronic kidney disease and non-alcoholic fatty liver disease.

Fixed-dose combination medicines, or polypills, have been proven to simplify treatment, enhance adherence, and better manage risk factors for cardiovascular disease.

These polypills combine cholesterol-lowering drugs, blood pressure medications, and aspirin as needed and significantly reduce morbidity and mortality from atherosclerotic cardiovascular diseases. Effective management of cardiovascular diseases could prevent millions of deaths over the next decades.

The demonstrated benefits and cost-effectiveness of these combinations earned them an inclusion in the WHO Essential Medicines List in 2023.
In this chapter we provide additional information on the medicines listed previously.

The detailed analysis is presented as a graphic snapshot following the prioritisation framework structure. Snapshots contain plain language key messages for each of the prioritisation criteria that MPP has evaluated.
HIV
Lenacapavir is a first-in-class capsid inhibitor, approved for treatment of multi-drug resistant HIV infection in adults. It is studied for HIV PrEP as a subcutaneous injection every 6 months and has a promising safety profile. Lenacapavir for PrEP would not require companion drugs. While it may have advantages in terms of adherence, health system requirements might be higher compared to once-daily oral PrEP options such as TDF/FTC. However, the upcoming access to long-acting cabotegravir for PrEP in LMICs will likely pave the way for a successful lenacapavir implementation, if proven safe and effective. In 2022, 39 million people globally were living with HIV and 1.3 million people became newly infected, most of which occurred in LMICs. Lenacapavir primary patents have been filed or granted in several LMICs and are expected to expire between 2034 and 2037. Gilead also holds secondary patents that may provide exclusivity until 2038 in many LMICs. This medicine is still in the R&D pipeline and therefore little is known about its potential positioning in treatment protocols, pricing, and overall access plans. While lenacapavir for PrEP is not approved by regulatory authorities yet, the formulation appears to be the same as the approved treatment.
**CLINICAL RELEVANCE**

Lenacapavir is a first-in-class capsid inhibitor, already approved for the treatment of multi-drug resistant HIV infection in adults as a subcutaneous injection every 6 months in combination with other daily ARVs. It has a promising safety profile studied as: a weekly oral HIV treatment in combination with islatravir, a daily oral regimen with bictegravir, a sub-cutaneous injections in association with monoclonal antibodies every 6 months.

**DISEASE BURDEN**

In 2022, 39 million people globally were living with HIV and 1.3 million people became newly infected, most of which occurred in LMICs.

**INTELLECTUAL PROPERTY LANDSCAPE**

Lenacapavir primary patents have been filed or granted in several LMICs and are expected to expire between 2034-2037. Gilead also holds secondary patents that may provide exclusivity until 2038 in many LMICs.

**SERVICE DELIVERY ENABLERS**

Lenacapavir's possible companion drugs are still under study. A six-monthly injectable regimen could aid adherence but may conflict with efforts to simplify and decentralize HIV treatment due to healthcare workers’ requirements for injections.

**REGULATORY**

Product approved by stringent regulatory authorities. Potential sublicensees of lenacapavir could rely on mechanisms like USFDA Paragraph III through PEPFAR (if included), Swissmedic MAGHP or EU-M4all or WHO Prequalification (if included) for quality assurance. Bioequivalence studies are necessary for oral solid formulations. Biowaivers will not be an option for oral solid formulations. There is a possibility of biowaiver for injectable products.

**MANUFACTURING**

A spray drying process is adopted for oral formulation. Injectable product is a standard solution, terminally sterilized. Standard excipients are used. The injectable formulation contains a specialised syringe along with vials. Shelf life is two years at room temperature for tablets and injectable product.

**MARKET**

While lenacapavir is currently approved by some major regulatory authorities for heavily treatment-experienced adults, it is not yet registered (and is therefore not available) in any LMICs. Access plans for lenacapavir in LMICs are not yet known.
**CLINICAL RELEVANCE**

Cabotegravir with rilpivirine is the only injectable long-acting regimen approved for HIV so far. This combination is safe and efficacious for HIV treatment, despite some challenges for use in LMICs. Recent implementation data indicate initial success in LMIC settings, paving the way to a broader adoption. Injectable cabotegravir and rilpivirine regimen for HIV treatment is not currently listed in WHO guidelines.

**DISEASE BURDEN**

In 2022, 39.0 million people globally were living with HIV and 1.3 million people became newly infected, most of which occurred in LMICs.

**INTELLECTUAL PROPERTY LANDSCAPE**

Primary patents on cabotegravir have been granted in many LMICs and are expected to expire in 2026. Secondary patents on the long-acting parenteral composition as well as intermediates and processes are expected to expire in 2031. MPP holds a licence with Viiv Healthcare for the use of cabotegravir for HIV PrEP.

Rilpivirine primary patent has expired except in a few countries where the term has been extended until 2026-2027. Secondary patents on the formulation are present in many LMICs and are expected to expire in 2027.

**MANUFACTURING**

The product requires sterile long-acting injectable nanosuspension formulation with specific requirements in terms of technology and manufacturing equipment. There are no anticipated challenges with respect to excipients. There is a requirement for special packaging for the medical device. Due to complex manufacturing technology, there are special manufacturing facility requirements. Shelf life is three years with refrigeration.

**MARKET**

Cabotegravir and rilpivirine long-acting combination for HIV treatment has been registered in a very few LMICs. Implementation trials are ongoing. Access plans are not yet known.

**REGULATORY**

The product is approved by stringent regulatory authorities. Potential sublicensees could possibly receive tentative approval from the USFDA for quality assurance. Pharmacokinetics (PK)-based bioequivalence studies will be required. Bioequivalence studies will be complex and long since it is a long-acting injectable. Biowaiver is not possible.

**SERVICE DELIVERY ENABLERS**

Cabotegravir is used in combination with rilpivirine as a long-acting injectable for the treatment of HIV. Rilpivirine has a cold chain requirement, limiting its potential for impact in LMICs. Transitioning to long-acting HIV treatment has adherence benefits, but the health system requirements may be higher than a daily oral regimen at primary healthcare or community levels.
CLINICAL RELEVANCE
Doravirine is approved for HIV treatment as a once-daily oral regimen in combination with other ARVs, and is currently being developed in combination with islatravir. Doravirine has shown efficacy and safety in children starting from 4 weeks of age. Doravirine has not yet been included in WHO treatment guidelines.

DISEASE BURDEN
In 2022, 39 million people globally were living with HIV and 1.3 million people became newly infected, most of which occurred in LMICs.

INTELLECTUAL PROPERTY LANDSCAPE
Primary patents on doravirine compound and its combinations with other anti-HIV agents or antivirals have been filed in many LMICs and are expected to expire in 2031. In a few countries, the patent term may be extended by another five years, until 2036. While bilateral voluntary licences have been granted to generic manufacturers for 86 countries, public information on such licences is limited.

REGULATORY
Product approved by stringent regulatory authorities. Potential sublicensees of doravirine could rely on mechanisms like USFDA Para III, Swissmedic MAGHP or EU-M4all for quality assurance. Bioequivalence studies are necessary. Biowaivers will not be an option.

SERVICE DELIVERY ENABLERS
DOR’s current companion drugs for HIV treatment are TDF/3TC (recommended by WHO with DTG and widely available in LMICs) and possibly islatravir. These oral daily regimens do not require different health system and infrastructure needs compared with the existing standard of care TDF/3TC/DTG (TLD).

MANUFACTURING
A spray drying process is adopted for the tablets. There are no anticipated challenges with respect to excipients or final packaging. No special requirements with respect to manufacturing facilities. Shelf life is 2.5 years at room temperature.

MARKET
Availability and affordability in LMICs are very low, as doravirine is generally not provided in most treatment programs.
Islatravir is a first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTTI) that is not yet approved. It is studied as a weekly oral HIV treatment in combination with lenacapavir and as an oral daily treatment in combination with doravirine.

In 2022, 39 million people globally were living with HIV and 1.3 million people became newly infected, most of which occurred in LMICs.

The product does not have regulatory approval yet and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

Islatravir’s current companion drugs being explored for HIV treatment, doravirine and lenacapavir, are currently not recommended by WHO for HIV treatment and may not be readily available in LMICs. An oral long-acting HIV treatment regimen could be an important option that would align with decentralised service delivery efforts.

Access plans for islatravir (and its investigated combinations) in LMICs are not yet known.

There is currently no adequate data to assess manufacturing complexity.

While islatravir primary patent is expected to expire in 2025, it has been granted in a few HICs only. There are secondary patents on a dosing regimen (less frequent than once-daily) in many LMICs with an expected expiry in 2037.
**Clinical Relevance**
mAbs/bNAb for PNP are still in early research, and clinical evidence in the field of prevention is limited; nonetheless, mAbs/bNAb for PNP hold significant potential, owing to the ease of a single injection and a favorable safety profile.

**Regulatory**
There are currently no approved mAbs/bNAb for HIV post-natal prophylaxis. Potential licensees could rely on mechanisms like EU-M4 all for quality assurance. Complete biosimilarity exercise with respect to analytical similarity, preclinical and clinical assessment likely to be done. Clinical trial waivers would likely not be an option. There could be additional regulatory complexities if a combination of bNAb is used.

**Service Delivery Enablers**
mAbs/bNAb for HIV post-natal prophylaxis are likely to be injectables administered intramuscularly or intravenously and require cold chain storage. As such, supply chain, health facility, and healthcare worker requirements may be minimised through the integration of mAbs/bNAb in national neonate immunization packages and corresponding administration at birth (for infants born to mothers living with HIV).

**Manufacturing**
Complex manufacturing process since the products are biotherapeutics. The products are still in early development and technical details are likely product-specific.

**Intellectual Property Landscape**
The patent landscape, likely to be complex, will depend on the specific candidates selected.

**Disease Burden**
About 500 children are newly infected with HIV every day. As of 2018, of the estimated nearly 38 million people worldwide living with HIV, approximately 1.7 million are children under 15 years of age. Since 2010, new HIV infections among children have declined by 41%, but only half (54%) of all children living with HIV are getting treatment and 100,000 children died of AIDS-related illnesses in 2018.

**Market**
Post-natal prophylaxis strategies are likely to be implemented in countries with high HIV burden, mostly LMICs.

**Watchlist**
- Potential product candidates
- Manufacturing challenges
- Regulatory hurdles
- Intellectual property considerations
- Disease burden and impact
- Market potential
- Supply chain and logistics
- Clinical trial design and waivers
TUBERCULOSIS
Quabodepistat is an investigational DprE1 inhibitor. This oral drug is in clinical development under the Project to Accelerate New Treatments for Tuberculosis (PAN-TB) program in combination with delamanid, bedaquiline, and sutezolid (DBOS) and in combination with pretomanid, bedaquiline and sutezolid (PBOS). It is also studied in combination with delamanid and bedaquiline without sutezolid. If successful, the PAN-TB regimens should provide improved safety and tolerability, a shorter duration, and be simpler to use than existing treatment options.

The availability of fully oral TB treatment regimens has simplified service delivery, but there remain health system requirements for diagnosis and monitoring and the implementation of directly-observed therapy (DOT); and while TB treatment has shortened in recent years, it still takes several months, which is challenging for adherence. A fully oral and shorter pan-TB regimen could be game-changing.

The primary patent on quabodepistat has been granted in many LMICs and is expected to expire in 2035. There are secondary patents on intermediates and combinations that may provide exclusivity until 2037-2039 in many LMICs.

Quabodepistat has not yet been approved by any regulatory authority and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

This medicine is still in the R&D pipeline and therefore little is known about its potential positioning in treatment protocols, pricing, and overall access plans.

In 2021, an estimated 10.6 million people fell ill with TB worldwide, of which 450,000 incident cases of rifampicin-resistant or multidrug-resistant TB. About 1.5 million people die from TB each year. Most of the people who fall ill with TB live in LMICs.
**CLINICAL RELEVANCE**

BTZ-043 is an investigational DprE1 inhibitor. Safety and efficacy data are still not mature.

**DISEASE BURDEN**

In 2022, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide, of which 450,000 incident cases of rifampicin-resistant or multidrug-resistant TB. About 1.5 million people die from TB each year. Most of the people who fall ill with TB live in LMICs.

**SERVICE DELIVERY ENABLERS**

BTZ-043, an oral TB treatment, may be paired with existing TB drugs, some not widely accessible.

**MANUFACTURING**

There is still no adequate data to assess manufacturing complexity.

**REGULATORY**

BTZ-043 does not have regulatory approval yet and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

**MARKET**

BTZ-043 is still in the R&D pipeline and therefore little is known about its potential positioning, pricing, and overall access plans.

**INTELLECTUAL PROPERTY LANDSCAPE**

BTZ-043 primary patent has been granted in many LMICs and is expected to expire in May 2026. Secondary patents have not been identified.

**WATCHLIST**

**TUBERCULOSIS**

Univ. Munich & DZIF
Delpazolid is a next-generation oxazolidinone antibiotic administered through oral and intravenous routes for the treatment of gram-positive bacterial infections including multidrug-resistant tuberculosis infections and pulmonary tuberculosis. Safety and efficacy data are still not mature.

The product does not have regulatory approval yet and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

Delpazolid is being developed as part of an oral TB treatment with bedaquiline, delamanid, and moxifloxacin, some of which are not widely accessible.

The primary patent on delpazolid is filed or granted in key countries of manufacture such as India, China, and South Africa and is expected to expire in 2029. Secondary patents with an expected expiry date in 2031 are filed or granted in a few LMICs.

In 2021, an estimated 10.6 million people fell ill with TB worldwide, of which 450,000 incident cases of rifampicin-resistant or multidrug-resistant TB. About 1.5 million people die from TB each year. Most of the people who fall ill with TB live in LMICs.

This medicine is still in the R&D pipeline and therefore little is known about its potential positioning, pricing, and overall access plans.

There is no adequate data to assess manufacturing complexity.

The product does not have regulatory approval yet and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.
**CLINICAL RELEVANCE**
Ganferobole is a Leucyl-tRNA synthetase inhibitor and it is not approved yet. Safety and efficacy data are still not mature.

**REGULATORY**
The product does not have regulatory approval yet and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

**SERVICE DELIVERY ENABLERS**
Ganfeborole is being investigated for use as part of an oral TB treatment. Companion drugs may include bedaquiline and delamanid, which are available as generics, although still not widely accessible.

**INTELLECTUAL PROPERTY LANDSCAPE**
Ganfeborole primary patents have been filed or granted in several LMICs and are expected to expire between 2031-2036. Secondary patents may be filed.

**DISEASE BURDEN**
In 2021, an estimated 10.6 million people fell ill with TB worldwide, of which 450 000 incident cases of rifampicin-resistant or multidrug-resistant TB. About 1.5 million people die from TB each year. Most of the people who fall ill with TB live in LMICs.

**MARKET**
This medicine is still in the R&D pipeline and therefore little is known about its potential positioning in treatment protocols, pricing, and overall access plans.

**MANUFACTURING**
There is currently no adequate data to assess manufacturing complexity.

**WATCHLIST**
Macozinone is a DprE1 inhibitor and is not approved yet. Its safety and efficacy data are still not mature.

In 2021, an estimated 10.6 million people fell ill with TB worldwide, of which 450,000 incident cases of rifampicin-resistant or multidrug-resistant TB. About 1.5 million people die from TB each year. Most of the people who fall ill with TB live in LMICs.

The product is not yet approved by any regulatory authority and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

Macozinone is being developed for use as part of an oral TB treatment. Its companion drugs are still unknown, but may include existing TB medicines, most of which are available as generics, although some are not widely accessible.

Primary patent on macozinone has been granted in key countries of manufacture such as India, China and South Africa and is expected to expire in 2031. Secondary patents may be filed.

This medicine is still in the R&D pipeline and therefore little is known about its potential positioning in treatment protocols, pricing, and overall access plans.
**CLINICAL RELEVANCE**
Sudapyridine is a bedaquiline analogue and it is not approved yet. Its safety and efficacy data are still not mature.

**REGULATORY**
Sudapyridine has not yet been approved by any regulatory authority and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

**SERVICE DELIVERY ENABLERS**
Sudapyridine is being developed as an oral drug. Its companion drugs are not known yet but, because of its chemical properties, it is likely to be developed as an alternative to bedaquiline in bedaquiline-containing regimens. Companion drugs may include existing TB medicines, most of which are available as generics, although some are not widely accessible.

**INTELLECTUAL PROPERTY LANDSCAPE**
Primary patents on sudapyridine are present in key countries of manufacture such as India, China and South Africa, and are expected to expire in 2035. Secondary patents covering manufacturing processes and intermediates with an expected expiry date in 2037 are present in a few LMICs.

**DISEASE BURDEN**
In 2021, an estimated 10.6 million people fell ill with TB worldwide, of which 450,000 incident cases of rifampicin-resistant or multidrug-resistant TB. About 1.5 million people die from TB each year. Most of the people who fall ill with TB live in LMICs.

**MARKET**
This medicine is still in the R&D pipeline and therefore little is known about its potential positioning in treatment protocols, pricing, and overall access plans.

**MANUFACTURING**
There is limited data at this stage to assess manufacturing complexity.
VIRAL HEPATITIS
**CLINICAL RELEVANCE**

Bulevirtide is approved by EMA and it has been shown to be an efficacious and well-tolerated treatment for the management of chronic HDV. Today, it is the only approved specific treatment for HDV. It needs to be injected subcutaneously every day for an undefined period.

**DISEASE BURDEN**

Globally, hepatitis delta virus (HDV) affects nearly 5% of people who have a chronic infection with HBV (HBV infections were estimated by WHO to be 296 million in 2019). HDV co-infection is associated with worse outcomes and could explain about 1 in 5 cases of liver disease and liver cancer in people with HBV infection.

**REGULATORY**

Bulevirtide is approved by the European Medicines Agency. Potential sublicensees of bulevirtide could rely on the EU-M4all mechanism for quality assurance. Comparative analytical characterization of the active pharmaceutical ingredient will be required, along with physicochemical comparison of formulation for bioequivalence. Biowaiver could be possible with qualitative and quantitative similarity (Q1/Q2).

**INTELLECTUAL PROPERTY LANDSCAPE**

The primary patent on bulevirtide is granted in key countries of manufacture such as India, China, Brazil and South Africa and is expected to expire in 2028. Secondary patents on long-acting formulations may be filed.

**SERVICE DELIVERY ENABLERS**

Bulevirtide is approved as monotherapy or in combination with nucleos(t)ide analogues for hepatitis B management. The diagnosis of HDV is challenging in most LMICs. When diagnosed with active HDV infection, people will need to attend an appropriately equipped health care facility (cold chain) to receive the reconstituted daily injection provided by trained medical staff.

**MANUFACTURING**

The product has a medium complexity associated with chemical manufacture of synthetic peptides (47 amino acids). The product is lyophilised. Aseptic processing is required. Shelf life is two years under refrigeration.

**MARKET**

Access plans for bulevirtide in LMICs are unknown. For its oral hepatitis C medicines, Gilead had issued voluntary licensing agreements to multiple manufacturers. It is unclear whether a similar approach would be taken for this medicine.
OTHER INFECTIOUS DISEASES
CLINICAL RELEVANCE

WHO estimates that in 2020, there were about 82.4 million new cases infected among adolescents and adults aged 15–49 years worldwide. Drug resistance to many treatment options makes Gonorrhea a major public health concern and WHO considers N. gonorrheae a priority pathogen. A recent press release from GSK announced that the EAGLE-1 trial met its primary efficacy endpoint, with gepotidacin (oral, two doses of 3,000mg) demonstrating non-inferiority to intramuscular (IM) ceftriaxone (500mg) plus oral azithromycin (1,000mg), a leading combination treatment regimen for gonorrhea.

DISEASE BURDEN

WHO estimates that in 2020, there were about 82.4 million new cases infected among adolescents and adults aged 15–49 years worldwide. Drug resistance to many treatment options makes Gonorrhea a major public health concern and WHO considers N. gonorrheae a priority pathogen.

INTELLECTUAL PROPERTY LANDSCAPE

GSK’s patents on gepotidacin and its use to treat bacterial infections in mammals, including urinary infections have been filed/granted in more than thirty LMICs and are expected to expire in 2028. Secondary patents on gepotidacin use to treat Neisseria gonorrhoeae infection have been filed in about forty LMICs with an expected expiry in 2036. Other secondary patents may provide exclusivity until 2042-2043.
PANDEMIC & EPIDEMIC THREATS
Baloxavir marboxil is approved by FDA for both the treatment and the prevention of influenza. A single-dose of baloxavir marboxil is safe and has superior efficacy to placebo and similar efficacy to oseltamivir (administered twice daily for 5 days) for ameliorating influenza symptoms in high-risk outpatients, with an 86% reduction in risk of developing clinical influenza. Baloxavir marboxil could prove to be a useful tool for addressing pandemic preparedness.

Primary patents on baloxavir marboxil have been filed or granted in several LMICs and they are expected to expire between 2030-2036. Secondary patents may provide exclusivity in a few LMICs until 2037.

The product approved by stringent regulatory authorities. Potential sublicensees of baloxavir marboxil could rely on mechanisms like USFDA Para III, Swissmedic MAGHP, EU-M4all or WHO Prequalification (if included) for quality assurance. Bioequivalence studies are necessary. Biowaivers will not be an option.

The production involves a standard manufacturing process for tablets. There are no challenges with respect to excipients or final packaging. Probable occupational exposure band (OEB) category 4; special facility might be required. Shelf life is at least three years at room temperature.

The product is currently available in a small number of LMICs at prices that are generally higher than oseltamivir. Based on an analysis of data of sales in HICs and UMICs where it is available, its price would be beyond the reach of most people and could potentially constitute a constraint on the ability of health systems in LMICs to respond to a possible influenza pandemic outbreak.
Nirsevimab showed efficacy versus placebo with respect to the medically attended RSV LRTI (relative risk reduction 79.5%), the RSV LRTI hospital admission (77.3%), and severe RSV (86%).

Nirsevimab is approved by stringent regulatory authorities. Potential licensees could rely on mechanisms like EU-M4all for quality assurance. Complete biosimilarity exercise with respect to analytical similarity, preclinical and clinical assessment needs to be done. Clinical trial waivers would not be an option.

Nirsevimab is an injectable monoclonal antibody, administered intramuscularly that requires cold chain storage. As such, supply chain, health facility, and healthcare worker requirements may be minimised through the integration of nirsevimab in national neonate immunization packages and corresponding administration at birth, especially as nirsevimab injection is deemed compatible with concomitant newborn vaccine injections.

Respiratory Syncytial Virus (RSV) is a leading cause of respiratory disease globally. RSV has been estimated to cause 34 million acute lower respiratory tract infections (LRTI) in young children annually, with over 3 million severe cases requiring hospitalization, and between 66,000 to 199,000 fatalities, 99% of which are in low- and middle-income countries (LMICs).

Nirsevimab is scarcely available even in private sectors in developed countries and there is no presence in LMICs. Nirsevimab’s price is estimated to be high (inherent to most monoclonal antibodies) and there is currently no information on access strategies for LMICs.

Complex manufacturing process since product is a monoclonal antibody. Aseptic processing is required. No challenges with respect to excipients. Final pack is pre-filled syringe (PFS), which would be considered as a device. Shelf life is two years under refrigeration.

Patents covering nirsevimab have been filed or granted in several LMICs and they are expected to expire between 2028 and 2035. Secondary patents covering a formulation and a treatment regimen with expiry dates in 2038 and 2040 were filed in several LMICs.

Nirsevimab is approved by stringent regulatory authorities. Potential licensees could rely on mechanisms like EU-M4all for quality assurance. Complete biosimilarity exercise with respect to analytical similarity, preclinical and clinical assessment needs to be done. Clinical trial waivers would not be an option.
CLINICAL RELEVANCE

Preliminary data shows that a single dose of clesrovimab could provide 74.2% efficacy for the prevention of medically attended lower respiratory tract RSV infection for a duration of 5 months in infants. However, these data are preliminary and more evidence on efficacy is needed.

DISEASE BURDEN

Respiratory Syncytial Virus (RSV) is a leading cause of respiratory disease globally. RSV has been estimated to cause 34 million acute lower respiratory tract infections (LRTI) in young children annually, with over 3 million severe cases requiring hospitalization, and between 66,000 to 199,000 fatalities, 99% of which are in low- and middle-income countries (LMICs).

INTELLECTUAL PROPERTY LANDSCAPE

Patents covering clesrovimab have been filed or granted in more than fifty LMICs and they are expected to expire in 2036. Secondary patents may be filed.

SERVICE DELIVERY ENABLERS

Clesrovimab is an injectable monoclonal antibody, likely to be administered intramuscularly and requires cold chain storage. As such, supply chain, health facility, and healthcare worker requirements may be minimised through the integration of clesrovimab in national neonate immunization packages and corresponding administration at birth.

MANUFACTURING

Complex manufacturing process since product is a monoclonal antibody. The product is still early in development and technical details are likely product specific.

REGULATORY

Clesrovimab is not approved by any stringent regulatory authorities. Potential licensees could rely on mechanisms like EU-M4 all for quality assurance. Complete biosimilarity exercise with respect to analytical similarity, preclinical and clinical assessment likely to be done. Clinical trial waivers likely would not be an option.

MARKET

Clesrovimab is not available yet in HIC or LMICs. Clesrovimab’s price is estimated to be high (as most of monoclonal antibodies) and there is currently no information on access strategies for LMICs.
CLINICAL RELEVANCE
Voxelotor significantly increased haemoglobin levels and reduced markers of haemolysis. These findings are consistent with inhibition of haemoglobin S (HbS) polymerization and indicate a disease-modifying potential in addition to the standard of care (hydroxyurea) or used in refractory/intolerance cases.

DISEASE BURDEN
In 2019, 605,000 people were born with sickle cell disease (SCD) and a total of 5.69 million were living with SCD. Sub-Saharan Africa is the region with the highest prevalence with about 75% of SCD cases occurring in sub-Saharan Africa. The mortality rate for children below five years of age ranges from 50% to 80%.

INTELLECTUAL PROPERTY LANDSCAPE
Voxelotor primary patents have been filed or granted in several LMICs and are expected to expire in 2032. Secondary patents may provide exclusivity in many LMICs until 2035-2037.

SERVICE DELIVERY ENABLERS
Access to diagnosis in low- and middle-income countries (LMICs) is still suboptimal causing high rates of mortality of children under five. Access to hydroxyurea, the usual first line treatment in LMICs, is still challenging in many countries.

REGULATORY
Product approved by stringent regulatory authorities. Potential sublicensees of voxelotor could rely on mechanisms like USFDA Paragraph III, EU-M4all for quality assurance. Bioequivalence studies are necessary. Biowaivers will not be an option.

MANUFACTURING
Standard manufacturing process for tablets. No challenges with respect to excipients or final packaging. Shelf life is three years at room temperature.

MARKET
The access strategy of voxelotor in LMICs is not known yet.
Elexacaftor/ivacaftor/tezacaftor has been shown to be superior to both placebo and the most performing CFTR modulator therapy tezacaftor/ivacaftor in improving lung functionality.

Ivacaftor and tezacaftor primary patents owned by Vertex are expected to expire between 2025 and 2028. Elexacaftor primary patents including its combination with tezacaftor and ivacaftor have been filed or granted in more than seventy LMICs with an expected expiry in 2037. Numerous secondary patents covering polymorphic forms, formulations, treatment regimens are present in many LMICs with an expected expiry dated between 2026-2039.

Worldwide, more than 162,428 people are estimated to be living with cystic fibrosis, of which 65% are diagnosed. The prevalence of cystic fibrosis is estimated to be 70,000 - 90,000 in the LMICs (very low certainty). The numbers are likely underestimates because of underdiagnosis. There is no cure and people with cystic fibrosis receive daily treatments depending on the severity of their symptoms.
ONCOLOGY
Immune checkpoint inhibitors (ICI), have revolutionised the landscape of cancer therapy, enabling long-term survival for a significant subset of patients, with some remaining cancer-free for years. These treatments are often better tolerated than traditional chemotherapy, significantly improving the quality of life for patients. ICIs have demonstrated considerable promise in treating a range of cancers previously deemed challenging, including melanoma, lung cancer, cervical cancer, and triple-negative breast cancers, marking a substantial advancement in the field.

Various immune checkpoint inhibitors are approved by stringent regulatory authorities. Potential sublicensees of these products could rely on mechanisms like Swissmedic MAGHP, EU-M4all for quality assurance. Complete biosimilarity exercise with respect to analytical similarity, preclinical and clinical assessment needs to be done. Clinical trial waivers would not be an option.

Access to immune checkpoint inhibitors is reported to be extremely low and challenging in LMICs.

Immune checkpoint inhibitors are usually registered in only a limited number of LMICs and are unaffordable to most of them being costlier than that of standard of care.

Cancer is the second leading cause of death worldwide, and 9.7 million deaths in 2022 were attributed to cancer. LMICs shoulder most of the cancer burden.

The patent status is product-dependent.
**CLINICAL RELEVANCE**

Pembrolizumab as a single agent reduces the risk of death in non-small cell lung cancer patients by 40%, significantly extending survival by more than a year with fewer side effects compared to traditional chemotherapy. Pembrolizumab is also indicated against several other cancers.

**DISEASE BURDEN**

Lung cancer stands as the second most frequent cancer worldwide, accounting for 1.7 million incident cases in LMICs during 2022.

**INTELLECTUAL PROPERTY LANDSCAPE**

MSD holds the exclusive patent rights on pembrolizumab until 2028 with patents filed or granted in at least 15 LMICs.

**MANUFACTURING**

Complex manufacturing process since product is a monoclonal antibody. Aseptic processing is required. No challenges with respect to excipients or final packaging. Shelf life is two years under refrigeration.

**REGULATORY**

Pembrolizumab is approved by stringent regulatory authorities. Potential sublicensees of pembrolizumab could rely on mechanisms like Swissmedic MAGHP, EU-M4all for quality assurance. Complete biosimilarity exercise with respect to analytical similarity, preclinical and clinical assessment needs to be done. Clinical trial waivers would not be an option.

**MARKET**

Pembrolizumab is registered in only a limited number of LMICs and is unaffordable to most of them being costlier than that of standard of care.

**SERVICE DELIVERY ENABLERS**

Access to pembrolizumab and other immune checkpoint inhibitors is reported to be extremely low and challenging in LMICs.
Aumolertinib, an investigational 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has demonstrated a consistent benefit in the time a patient can live without disease progression and a lower rate of adverse events leading to permanent discontinuation compared to gefitinib.

Lung cancer is the most diagnosed and the first cause of death from cancer worldwide, with an estimated 2.5 million new cases and 1.8 million related deaths in 2022. 80% are classified as non-small cell cancers (NSCLC). The EGFR mutation is present in 30% of these cases and almost 60% of these cases are diagnosed in advanced stages.

Aumolertinib does not have stringent regulatory authorities (SRA) approval yet and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

Lung cancer is still underdiagnosed in many LMICs, especially where there is a higher burden of tuberculosis. While basic imaging tests are available in the public sector of LMICs, patients are often identified at an advanced/metastatic setting. EGFR PCR testing is becoming increasingly available also in the public sector of some LMICs, also thanks to the availability of generic first and second generation of EFGR TKIs.

Aumolertinib compound patent is expected to expire in 2035, and it has been granted in key countries of manufacture such as India, China and South Africa. Secondary patents may provide exclusivity in few LMICs until 2036-2039.

Aumolertinib is currently approved only in very few countries. Access plans for it in LMICs are currently unknown.
Clinical Relevance

Osimertinib, a 3rd generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is the preferred option for the treatment of early stages of locally advanced NSCLC and for treatment of metastatic NSCLC with EGFR-activating mutation. Patients who received osimertinib had longer overall survival than those who received gefitinib, a 1st generation EGFR TKI.

Regulatory

Product approved by stringent regulatory authorities. Potential sublicensees of osimertinib could rely on mechanisms like USFDA Paragraph III, Swissmedic MAGHP, EU-M4all for quality assurance. Bioequivalence studies will be required. Biowaivers might not be possible.

Service Delivery Enablers

Lung cancer is still underdiagnosed in many LMICs. Basic imaging tests are available in the public sector of LMICs however, patients are often identified at an advanced/metastatic setting. EGFR PCR testing is becoming increasingly available also in the public sector of LMICs, also thanks to the availability of generic first and second generation of EGFR TKIs.

Intellectual Property Landscape

The primary patent on osimertinib is expected to expire in 2032 and has been granted in more than 60 LMICs.

Disease Burden

Lung cancer is the most diagnosed and the first cause of death from cancer worldwide, with an estimated 2.5 million new cases and 1.8 million related deaths in 2022. 80% are classified as non-small cell cancers (NSCLC). The EGFR mutation is present in 30% of these cases and almost 60% of these cases are diagnosed in advanced stages.

Market

Osimertinib is available in some LMICs primarily in the private sector. It is one of the costliest medicines in the NSCLC segment and is generally not affordable to most people with lung cancer in LMICs. Access plans of osimertinib are not known yet.

Manufacturing

Standard manufacturing process for tablets. No challenges with respect to excipients or final packaging. Probable occupational exposure band (OEB) category 4, special facility might be required. Shelf life is three years at room temperature.
Abemaciclib, in addition to endocrine therapy, significantly improve progression-free survival of patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, while maintaining a safe profile compared to placebo.

Abemaciclib primary patents have been granted in more than 40 LMICs and are expected to expire in 2029 in most countries.

Diagnosis of breast cancer is provided in the public health sector in many LMICs, however with significant delays. Consequently, a high proportion of cases is only detected at an advanced/metastatic stage of the disease. Generic companion treatments are usually available.

Abemaciclib is approved by stringent regulatory authorities. Potential sublicensees of abemaciclib could rely on mechanisms like EU-M4all or Swissmedic MAGHP for quality assurance. Current guidance mentions the requirement of PK-based bioequivalence studies, however biowaiver options can be explored.

Abemaciclib is available primarily in the private markets of a small number of LMICs. However, it is more expensive than other hormonal receptor inhibitors.

Among women, breast cancer is the most frequently diagnosed cancer and the leading worldwide cause of cancer-related death. About two-thirds of breast cancers in women aged 50 years or younger are HR positive and HER2 negative.

Standard manufacturing process for tablets. No challenges with respect to excipients or final packaging. Probable occupational exposure bands (OEB) category 4, special facility might be required. Shelf life is three years at room temperature.
The addition of ribociclib to endocrine therapy, the usual initial treatment, resulted in significantly longer overall survival than endocrine therapy alone. About 70% of people in the ribociclib group were still alive after 42 months, while only 46% were alive in the placebo group.

Diagnosis of breast cancer is provided in the public health sector in many LMICs, but a high proportion of cases is only detected at an advanced/metastatic stage of the disease. Generic companion treatments are usually available.

Ribociclib primary patents have been filed or granted in many LMICs and are expected to expire between 2027 and 2029. Secondary patents may provide exclusivity until 2031-2036 in many LMICs.

Product approved by stringent regulatory authorities. Potential sublicensees of ribociclib could rely on mechanisms like USFDA Para III, Swissmedic MAGHP, EU-M4all for quality assurance. Bioequivalence studies are necessary. Biowaivers will not be an option.

Standard manufacturing process for tablets. No challenges with respect to excipients or final packaging. Probable occupation exposure band (OEB) category 4, special facility might be required. Shelf life is three years at room temperature.

Ribociclib is available in several LMICs, primarily in the private sector, but affordability remains a challenge. Access plans for ribociclib are not known yet.

Among women, breast cancer is the most frequently diagnosed cancer and the leading worldwide cause of cancer-related death. About two-thirds of breast cancers in women aged 50 years or younger are HR positive and HER2 negative.
Cancer-free survival is significantly improved in HER2-positive breast cancer patients who receive one year of trastuzumab treatment after adjuvant chemotherapy. The subcutaneous administration method is quicker, saving time and money to health systems, and is preferred by patients compared to the intravenous formulation.

Product approved by stringent regulatory authorities. Potential sublicensees could of trastuzumab subcutaneous could rely on mechanisms like Swissmedic MAGHP, EU-M4all or WHO PQ (if included in pilot program) for quality assurance. Complete biosimilarity exercise with respect to analytical similarity, preclinical and clinical assessment needs to be done. Phase III clinical trial waiver might be possible if there is already an approved intravenous product by the applicant.

Diagnosis of breast cancer is provided in the public health sector in many LMICs, but a high proportion of cases is only detected at an advanced/metastatic stage of the disease. Generic companion treatments are usually available. The subcutaneous formulation could simplify service delivery and enable more people to be treated with the existing health infrastructure in LMICs.

Complex manufacturing process since product is a monoclonal antibody. Aseptic processing is required. Occupation exposure band (OEB) level 3, manufacturing precautions necessary. Hyaluronidase, a biologic, is added as excipient. There are no anticipated challenges with respect to final packaging. Shelf life is 21 months under refrigeration.

While biosimilar formulations of intravenous trastuzumab are available in many LMICs, subcutaneous formulation availability is very limited and hence its access in many LMICs, despite its advantages for patients and health systems.
**Clinical Relevance**
Ibrutinib treatment, when used as the first option for CLL patients, continues to provide better survival and delays cancer progression compared to chemotherapy for up to eight years.

**Disease Burden**
Chronic Lymphocytic Leukaemia (CLL) is the most common type of leukaemia in Western countries, making up about 25% to 30% of all leukaemia cases. In some countries of Central Sub-Saharan Africa, the death rate from CLL is rising rapidly.

**Regulatory**
Product approved by stringent regulatory authorities. Potential sublicensees of ibrutinib can rely on mechanisms adopt standard registration procedures like USFDA Paragraph III, Swissmedic MAGHP, EU-M4all. Bioequivalence studies are necessary. Biowaivers will not be an option.

**Service Delivery Enablers**
CLL is a relatively rare condition in LMICs. Access to diagnosis is still challenging. Blood count capacity is widely available, but more sophisticated tests required for the diagnosis are scarcely available or affordable in the majority of LMICs.

**Intellectual Property Landscape**
Ibrutinib primary patent expires in 2026 and it has been granted in few LMICs, including India. Secondary patents with expiry dates ranging between 2031 and 2036 covering formulations, methods of treatment or crystalline forms are present in many LMICs.

**Disease Burden**
Chronic Lymphocytic Leukaemia (CLL) is the most common type of leukaemia in Western countries, making up about 25% to 30% of all leukaemia cases. In some countries of Central Sub-Saharan Africa, the death rate from CLL is rising rapidly.

**Market**
Ibrutinib appears to be more expensive than standard chemotherapy drugs such as bendamustine and fludarabine. It is scarcely available and affordable in the public domain in LMICs.

**Manufacturing**
Standard manufacturing process for oral formulation. No challenges with respect to excipients or final packaging. Probable occupational exposure band (OEB) category 3, manufacturing precautions may be required. Shelf life is three years at room temperature for tablets and capsules and two years at 2°C to 25°C for oral suspension.
**Clinical Relevance**
After median follow-up of 26 months, the progression-free survival was significantly longer with zanubrutinib compared to chemoimmunotherapy.

**Disease Burden**
Chronic Lymphocytic Leukaemia (CLL) is the most common type of leukaemia in Western countries, making up about 25% to 30% of all leukaemia cases. In some countries of Central Sub-Saharan Africa, the death rate from CLL is rising rapidly.

**Regulatory**
Zanubrutinib is approved by stringent regulatory authorities. Potential sublicensees of zanubrutinib could rely on mechanisms like USFDA Para III, EU-M4all or Swissmedic MAGHP for quality assurance. Bioequivalence studies are necessary. Biowaivers will not be an option.

**Service Delivery Enablers**
CLL is a relatively rare condition in LMICs. Access to diagnosis is still challenging. Blood count capacity is widely available, but more sophisticated tests required for the diagnosis are scarcely available or affordable in the majority of LMICs. Zanubrutinib can be used in monotherapy or in combination with other agents, the availability of which may be challenging in many countries.

**Intellectual Property Landscape**
The primary patent on zanubrutinib was granted in few LMICs, including India, where it is expected to expire in 2034. Secondary patents on crystalline forms are expected to expire in 2037.

**Manufacturing**
Standard manufacturing process for oral capsules. There are no anticipated challenges with respect to excipients or final packaging. Shelf life is three years at room temperature.

**Market**
Zanubrutinib is available in very few LMICs. Beigene has recently announced a partnership with the Max Foundation focused on 29 LMICS over the next three years.

**Priority List**
CLINICAL RELEVANCE
Adagrasib led to durable clinical benefit in patients with previously treated, advanced KRAS-mutated NSCLC. Adagrasib is being evaluated as monotherapy and in combination with other therapies in NSCLC.

DISEASE BURDEN
Lung cancer is the most diagnosed and the first cause of death from cancer worldwide, with an estimated 2.5 million new cases and 1.8 million related deaths in 2022. 80% are classified as non-small cell lung cancers (NSCLC). Activating mutations in KRAS (Kirsten rat sarcoma virus) viral oncogene homologue are found in 25 to 30% of NSCLC.

INTELLECTUAL PROPERTY LANDSCAPE
Adagrasib primary patents have been filed in many LMICs and are expected to expire in 2038.

SERVICE DELIVERY ENABLERS
Lung cancer is still underdiagnosed in many LMICs, especially where there is a higher burden of tuberculosis. While basic imaging tests are available in the public sector of LMICs, patients are often identified at an advanced/metastatic setting. PCR testing capacity is becoming increasingly available also in the public sector of LMICs.

REGULATORY
The product is approved by stringent regulatory authorities. Potential sublicensees of adagrasib could rely on mechanisms like USFDA Paragraph III for quality assurance. Bioequivalence studies are necessary. Biowaivers will not be an option.

MARKET
Adagrasib is Mirati’s first commercial product, approved in very few countries (none of which are LMICs). Access plans are not known yet.

MANUFACTURING
Standard manufacturing process for tablets. No challenges with respect to excipients or final packaging. Occupational Exposure Limit (OEL) is not known. Shelf life is at least two years at room temperature.
Lazertinib, a 3rd generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), demonstrated significant improvement in the time a patient can live without disease progression compared with gefitinib, a 1st generation EGFR TKI.

Lazertinib is only approved in the Republic of Korea so far and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

Lung cancer is the most diagnosed and the first cause of death from cancer worldwide, with an estimated 2.5 million new cases and 1.8 million related deaths in 2022. 80% are classified as non-small cell cancers (NSCLC). The EGFR mutation is present in 30% of these cases and almost 60% of these cases are diagnosed in advanced stages.

The primary patent on lazertinib has been granted in many LMICs including India and is expected to expire in 2034. There are secondary patents that may provide further exclusivity until 2038-2041 in many LMICs.

Although the product got its first approval in 2021, it is still pricier than first-generation EGFR TKI inhibitors. There is no information on its access and availability in LMICs.

There is currently limited data available to assess the manufacturing complexity of lazertinib.
CLINICAL RELEVANCE
Sotorasib significantly increased the time a patient, with advanced NSCLC presenting the KRAS mutation, can live without disease progression and had a more favourable safety profile compared with docetaxel, a conventional chemotherapy drug.

DISEASE BURDEN
Lung cancer is the most diagnosed and the first cause of death from cancer worldwide, with an estimated 2.5 million new cases and 1.8 million related deaths in 2022. 80% are classified as non-small cell lung cancers (NSCLC). Activating mutations in KRAS (Kirsten rat sarcoma virus) viral oncogene homologue are found in 25 to 30% of NSCLC.

SERVICE DELIVERY ENABLERS
Lung cancer is still underdiagnosed in many LMICs. Basic imaging tests are available in the public sector of LMICs however, patients are often identified at an advanced/metastatic setting. PCR testing capacity is becoming increasingly available also in the public sector of LMICs.

INTELLECTUAL PROPERTY LANDSCAPE
The primary patent on sotorasib has been granted in many LMICs and is expected to expire in 2038. Several secondary patents on crystalline forms and processes are expected to expire between 2039 and 2040.

MANUFACTURING
Standard manufacturing process for tablets. No challenges with respect to excipients or final packaging. Probable Occupational Exposure Band (OEB) category 3, manufacturing precautions necessary. Shelf life is three years at room temperature.

MARKET
Sotorasib is currently available in very few LMICs and is generally pricier than standard of care. Access plans are currently unknown.

REGULATORY
Product approved by stringent regulatory authorities. Potential sublicensees of sotorasib could rely on mechanisms like USFDA Paragraph III, Swissmedic MAGHP, EU-M4all for quality assurance. Bioequivalence studies are necessary. Biowaivers will not be an option.
**CLINICAL RELEVANCE**

Among men with nonmetastatic castration-resistant prostate cancer already receiving androgen-deprivation therapy (the standard of care for this condition), the metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo.

**DISEASE BURDEN**

Prostate cancer is the second most common cancer in men and the fourth most common cancer overall (7.3% of all new cancer cases in 2022). Prostate cancer incidence rates are rising in many populations in Sub-Saharan Africa where men are approximately twice as likely to be diagnosed with prostate cancer before the age of 45 as Caucasian men.

**SERVICE DELIVERY ENABLERS**

Prostate cancer diagnosis in LMICs is hindered by limited access to diagnostic tools and healthcare resources. Prostate Specific Antigen (PSA) testing, imaging, and biopsies are scarce, leading to late-stage diagnosis. Access to cost-effective second-line androgen-targeted therapies like abiraterone and enzalutamide is also inadequate in many LMICs.

**INTELLECTUAL PROPERTY LANDSCAPE**

Apalutamide primary patents are expected to expire in 2027. Secondary patents may provide exclusivity until 2033-2038 in many LMICs.

**MANUFACTURING**

Solid dispersion technique is used for manufacture of tablets. No challenges with respect to excipients or final packaging. Since it is an androgenic receptor inhibitor, special facility might be required. Shelf life is three years at room temperature.

**REGULATORY**

Product approved by stringent regulatory authorities. Potential sublicensees of apalutamide could rely on mechanisms like USFDA Paragraph III, Swissmedic MAGHP or EU-M4all for quality assurance. Bioequivalence studies are necessary. Biowaivers will not be an option.

**MARKET**

The product’s growth is evidenced by presence in >75 countries including a few LMICs, generic versions are available. However, there seems to be limited access in the public sector.
CLINICAL RELEVANCE
Among men with nonmetastatic castration-resistant prostate cancer already receiving androgen-deprivation therapy (the standard of care for this condition), the percentage of patients who were alive at three years was significantly higher among those who received darolutamide than among those whose received placebo.

DISEASE BURDEN
Prostate cancer is the second most common cancer in men and the fourth most common cancer overall (7.3% of all new cancer cases in 2022). Prostate cancer incidence rates are rising in many populations in Sub-Saharan Africa where men are approximately twice as likely to be diagnosed with prostate cancer before the age of 45 as Caucasian men.

SERVICE DELIVERY ENABLERS
Prostate cancer diagnosis in LMICs is hindered by limited access to diagnostic tools and healthcare resources. PSA testing, imaging, and biopsies are scarce, leading to late-stage diagnosis. Access to cost-effective second-line androgen-targeted therapies like abiraterone and enzalutamide is also inadequate in many LMICs.

MANUFACTURING
Standard manufacturing process for tablets. No challenges with respect to excipients or final packaging. Probable occupational exposure band (OEB) category 3 manufacturing precautions might be required. Shelf life is three years at room temperature.

INTELLECTUAL PROPERTY LANDSCAPE
Darolutamide primary patent has been granted in many LMICs and is expected to expire in May 2030. The patent term has been extended in few LMICs until 2035. Secondary patents have not been identified in LMICs.

REGULATORY
Product approved by stringent regulatory authorities. Potential sublicensees of darolutamide could rely on mechanisms like USFDA Para III, Swissmedic MAGHP, EU-M4all for quality assurance. Bioequivalence studies are necessary. Biowaivers will not be an option.

MARKET
Darolutamide’s growth is evidenced by its availability in more than 80 countries including some LMICs. However, it is scarcely available in the public domain and there seems to be no information on its access strategies in LMICs.
CLINICAL RELEVANCE
Paclitaxel is part of the taxane class which is used in oncology treatments for a variety of cancers, including breast, lung, prostate, stomach and ovarian cancers, among others and is an integral part of the standard of care. An oral formulation of paclitaxel, enabled by encequidar, a novel P-glycoprotein pump inhibitor, is attractive due to its ease of administration, which could include the option for patients to take it at home without requiring intravenous access.

INTELLECTUAL PROPERTY LANDSCAPE
While paclitaxel is off patent and encequidar primary patent is to expire in early 2024, Hanmi owns patents on paclitaxel oral formulation as well as on the combination that have been filed or granted in many LMICs with an expected expiry in 2036. Additional secondary patents on encequidar have been filed in many LMICs and are expected to expire between 2031 and 2033.

DISEASE BURDEN
Cancer is the second leading cause of death worldwide, and 9.7 million deaths in 2022 were attributed to cancer. Low-and-middle-income countries (LMICs) shoulder most of the cancer burden.

SERVICE DELIVERY ENABLERS
Service delivery enablers change according to the type of cancer assessed. In general, capacity of cancer diagnosis is slowly improving in LMICs. Oral therapies represent an opportunity to facilitate the delivery of treatment.

MANUFACTURING
There is currently limited data available to assess the manufacturing complexity of oral paclitaxel.

MARKET
This medicine is still in the research and development pipeline and therefore little is known about its potential positioning in treatment protocols, pricing, and overall access plans.

REGULATORY
Oral paclitaxel has not yet been approved by any regulatory authority and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.

WATCHLIST
DIABETES, CARDIOVASCULAR & METABOLIC DISORDERS
CLINICAL RELEVANCE

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) stand at the forefront of diabetes management by playing not only a pivotal role in glycaemic control but also in promoting weight loss. Beyond their metabolic effects, some GLP-1 RAs have also been associated with a reduction of the risks of cardiovascular events in patients.

INTELLECTUAL PROPERTY LANDSCAPE

The patent status is product dependent.

REGULATORY

Various GLP-1 receptor agonists are approved by stringent regulatory authorities. Potential sublicensees of these products could rely on mechanisms like Swissmedic MAGHP, EU-M4all for quality assurance. Complete biosimilarity exercise with respect to analytical similarity, preclinical and clinical assessment needs to be done. Clinical trial waivers would not be an option.

SERVICE DELIVERY ENABLERS

While new agents are effective and safe in achieving diabetes control, LMICs still rely on older drug classes mainly due to cost. Increased access to better medicines for the control of diabetes may help fill the treatment-to-control gap (where nearly 40% of treated patients do not achieve control), while other efforts should also aim at increasing diagnosis (where more than 50% of all patients are missed).

MARKET

There is currently low access to GLP-1 receptor agonists in several LMIC markets and pricing is relatively high compared to other therapies used in diabetes that are now genericised.

MANUFACTURING

The manufacturing processes are product dependent.

DISEASE BURDEN

Type 2 diabetes (T2DM), the most prevalent form of diabetes globally, represents over 90% of cases and is on the rise in all demographics, including children and adolescents, partly due to increasing obesity rates. Those with diabetes have a higher risk of developing cardiovascular diseases.

DISEASE & CARDIOVASCULAR HEALTH

Multiple patent holders
Annex: Prioritisation framework
The assessment framework proposed to be applied to each product has the following arborescence:

Each sub-criteria is accompanied by an explanation of how the information gathered will likely be used in assessing the potential of an MPP intervention for the product in question. The final decision on product prioritisation is at the discretion of the prioritisation committee.
## 1. PUBLIC HEALTH CONSIDERATIONS

### 1.1. Disease burden

#### CRITERIA FOR PRODUCT’S ASSESSMENT

<table>
<thead>
<tr>
<th>N</th>
<th>CRITERIA</th>
<th>SUB-CRITERIA</th>
<th>EXPLANATION OF THE CRITERIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Prevalence/incidence</td>
<td>BURDEN OF DISEASE IN LMICS (GLOBAL OR LOCAL)</td>
<td>The burden of the disease in LMICs (global) or in specific LMIC regions or countries (local).</td>
</tr>
<tr>
<td>2</td>
<td>Prevalence/incidence</td>
<td>BURDEN OF DISEASE IN SPECIFIC POPULATIONS</td>
<td>The burden of the condition in key populations (PLHIV, pregnant and lactating individuals, pediatric populations, and adolescents, people who inject drugs (PWID), incarcerated individuals, sex workers, and any other vulnerable groups).</td>
</tr>
<tr>
<td>3</td>
<td>Treatment options</td>
<td>LACK OF ALTERNATIVE TREATMENTS</td>
<td>Whether there is a lack of alternative treatment for the product-specific indication.</td>
</tr>
<tr>
<td>4</td>
<td>Disease severity</td>
<td>DISABILITY-ADJUSTED LIFE YEARS (DALYs)</td>
<td>Disability-adjusted life years (DALYs) as a measure of disease severity.</td>
</tr>
<tr>
<td>5</td>
<td>Disease severity</td>
<td>NUMBER OF DEATHS</td>
<td>Yearly estimated deaths linked directly or indirectly to the condition.</td>
</tr>
<tr>
<td>6</td>
<td>Epidemic risk</td>
<td>EPIDEMIC/PANDEMIC RISK</td>
<td>Whether there is a risk for imminent or future outbreaks of the disease.</td>
</tr>
</tbody>
</table>

### 1.2. Clinical relevance

#### CRITERIA FOR PRODUCT’S ASSESSMENT

<table>
<thead>
<tr>
<th>N</th>
<th>CRITERIA</th>
<th>SUB-CRITERIA</th>
<th>EXPLANATION OF THE CRITERIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>Safety</td>
<td>SAFETY/TOLERABILITY</td>
<td>Overall safety and tolerability profile of the product.</td>
</tr>
<tr>
<td>8</td>
<td>Safety</td>
<td>DRUG-DRUG INTERACTIONS (DDI) WITH HIGH-BURDEN DISEASES REGIMENS</td>
<td>Drug-drug interactions (DDI) with standard of care (SoC) for high-burden infectious diseases such as HIV, TB, and Hepatitis C, and other DDIs.</td>
</tr>
<tr>
<td>9</td>
<td>Safety</td>
<td>PRODUCT-INDUCED ADVERSE EVENTS</td>
<td>Whether the product causes adverse events (e.g. hepatotoxicity, nephrotoxicity, weight gain, hypertension).</td>
</tr>
<tr>
<td>N</td>
<td>CRITERIA</td>
<td>SUB-CRITERIA</td>
<td>EXPLANATION OF THE CRITERIA</td>
</tr>
<tr>
<td>----</td>
<td>-------------------------------</td>
<td>------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>10</td>
<td>Safety</td>
<td>SPECIAL ADMINISTRATION RESTRICTIONS</td>
<td>Special administration restrictions such as fasting, or requirements for food intake.</td>
</tr>
<tr>
<td>11</td>
<td>Efficacy</td>
<td>EFFICACY</td>
<td>Overall efficacy compared to SoC. Efficacy should be ideally superior to the SoC. If the efficacy is comparable to SoC, then an additional advantage should be present. If the efficacy is inferior to the SoC, then product should be excluded from the evaluation.</td>
</tr>
<tr>
<td>12</td>
<td>Efficacy</td>
<td>ADHERENCE</td>
<td>Facilitated adherence to the product compared to SoC (from user/caregiver perspective).</td>
</tr>
<tr>
<td>13</td>
<td>Efficacy</td>
<td>GENETIC BARRIER TO RESISTANCE</td>
<td>When relevant. Whether there is a high genetic barrier to resistance, especially important for long/life treatment duration.</td>
</tr>
<tr>
<td>14</td>
<td>Efficacy</td>
<td>KNOWN RESISTANCE MUTATIONS</td>
<td>When relevant. Whether the product has known significant viral/bacterial resistance mutations of concern.</td>
</tr>
<tr>
<td>15</td>
<td>Efficacy</td>
<td>SPECTRUM</td>
<td>When relevant. Whether the product covers several diseases or all disease sub-types (e.g. Hepatitis C pan-genotypic treatment, multi-purpose technology, latent and active TB, several sexually transmitted infections (STIs), several cancers, etc.).</td>
</tr>
<tr>
<td>16</td>
<td>Efficacy</td>
<td>INNOVATIVE PRODUCT</td>
<td>Whether the product is innovative (such as a new promising mechanism of action, breakthrough therapy designation, orphan drug designation etc.).</td>
</tr>
<tr>
<td>17</td>
<td>Posology &amp; method of</td>
<td>DOSAGE</td>
<td>Dosage for each indication (e.g. mg, mg/kg, mg/m2).</td>
</tr>
<tr>
<td></td>
<td>administration</td>
<td></td>
<td>Duration of the treatment for the main and secondary indications.</td>
</tr>
<tr>
<td>18</td>
<td>Posology &amp; method of</td>
<td>FREQUENCY OF ADMINISTRATION</td>
<td>The frequency of dosing (e.g. once or twice daily or every 6 months).</td>
</tr>
<tr>
<td></td>
<td>administration</td>
<td></td>
<td>Whether a pediatric formulation/development program is available.</td>
</tr>
<tr>
<td>19</td>
<td>Posology &amp; method of</td>
<td>AVAILABILITY OF A PEDIATRIC FORMULATION</td>
<td>Route of administration and concise instructions for correct administration and use.</td>
</tr>
<tr>
<td></td>
<td>administration</td>
<td></td>
<td>Synergies with other health areas i.e., whether the product could be used across several diseases.</td>
</tr>
</tbody>
</table>

We used the following age ranges:

**PEDIATRIC**
- Birth
- 28 Days
- 2 Years
- 10 Years
- 19 Years
- Neonates
- Infants and toddlers
- Children
- Adolescents

**ADULTS**
- 20 Years
- 64 Years

**OLDER ADULTS**
- 65 Years
## ACCESS CONSIDERATIONS

### 2.1. Intellectual property landscape

<table>
<thead>
<tr>
<th>N</th>
<th>CRITERIA</th>
<th>SUB-CRITERIA</th>
<th>EXPLANATION OF THE CRITERIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>Years to patent expiry of API</td>
<td>YEARS TO PATENT EXPIRY OF API</td>
<td>Number of years of blocking patent protection left on the API.</td>
</tr>
<tr>
<td>24</td>
<td>Geographical coverage of patents</td>
<td>GEOGRAPHICAL COVERAGE OF PATENTS (INCLUDING SECONDARY PATENTS)</td>
<td>Country scope: how many LMICs are covered.</td>
</tr>
<tr>
<td>25</td>
<td>Secondary patents</td>
<td>SECONDARY PATENTS</td>
<td>Specific secondary patents (e.g. formulation, process, method of treatment, platforms) or patent thicket (e.g. biologics).</td>
</tr>
<tr>
<td>26</td>
<td>Multiple patent owners</td>
<td>MULTIPLE PATENT OWNERS</td>
<td>If multiple patent owners, might be lengthier to find an agreement with all the involved parties.</td>
</tr>
</tbody>
</table>

### 2.2. Service delivery enablers

<table>
<thead>
<tr>
<th>N</th>
<th>CRITERIA</th>
<th>SUB-CRITERIA</th>
<th>EXPLANATION OF THE CRITERIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>Diagnostic</td>
<td>REQUIREMENTS FOR DIAGNOSIS</td>
<td>Diagnostic requirements for the diagnosis of the disease.</td>
</tr>
<tr>
<td>28</td>
<td>Diagnostic</td>
<td>ACCESS TO DIAGNOSIS</td>
<td>It includes an evaluation on availability/affordability/status awareness of the diagnosis. It also includes info on whether the diagnosis is generally available in the public sector or only in the private one. A subset of countries is taken as a proxy.</td>
</tr>
<tr>
<td>29</td>
<td>Diagnostic</td>
<td>REQUIREMENTS FOR TREATMENT ELIGIBILITY/TREATMENT MONITORING</td>
<td>Additional diagnostic requirements required to define eligibility to treatment candidate compared to SoC (e.g. sequencing) / requirement for treatment monitoring (e.g. viral testing).</td>
</tr>
<tr>
<td>30</td>
<td>Companion drugs</td>
<td>COMPANION DRUG REQUIREMENTS</td>
<td>Need of companion treatments.</td>
</tr>
<tr>
<td>31</td>
<td>Companion drugs</td>
<td>ACCESS TO COMPANION DRUGS</td>
<td>Access (availability and affordability) to companion treatment/s.</td>
</tr>
<tr>
<td>32</td>
<td>Health system requirements</td>
<td>HEALTH SYSTEM AND INFRASTRUCTURE NEEDS</td>
<td>Additional requirements for the proper and safe use of the candidate e.g. specific treatment efficacy and/or safety requirements/staff training/facilities.</td>
</tr>
</tbody>
</table>
### CRITERIA FOR PRODUCT’S ASSESSMENT

<table>
<thead>
<tr>
<th>N</th>
<th>CRITERIA</th>
<th>SUB-CRITERIA</th>
<th>EXPLANATION OF THE CRITERIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>33</td>
<td>Manufacturing simplicity</td>
<td>MANUFACTURING</td>
<td>This includes the simplicity of the manufacturing process generally for this class of molecules. Small molecules chemically manufactured are classified as &quot;not particularly complex for manufacturing&quot;. Synthetic proteins or nucleic acids are considered as partially complex manufacturing as it is less standard process than small molecules and requires generally aseptic filling which demands specific competencies. Recombinant proteins are classified as complex manufacturing as these involve cell growth steps and specific characterization tools needing specific competencies, and it generally also requires aseptic filling. Any specificity of this product within its category is ranked in the criteria as standard manufacturing operations.</td>
</tr>
<tr>
<td>34</td>
<td>Manufacturing simplicity</td>
<td>MANUFACTURING OPERATIONS</td>
<td>Compared to the general simplicity to manufacture this category of product, any complexity to manufacture this specific product is ranked here (e.g., non-standard manufacturing step requiring specific competency or investment).</td>
</tr>
<tr>
<td>35</td>
<td>Manufacturing simplicity</td>
<td>MANUFACTURING FACILITY</td>
<td>Special requirements in terms of manufacturing facilities are captured here. Higher value of MPP intervention is attributed to products with no specific facility requirement other than basic good manufacturing practices (GMP), for example non-sterile products. Medium rating is attributed to products which require some additional control in terms of facility, like requirement of grade C area for sterile products which can be sterilised by terminal sterilisation. Lower value of MPP intervention is attributed to products which would require aseptic processing (Grade A) or special containment like hormones or oncology products with occupational exposure limits (OEL) classification of 4 or 5, thus making likely more challenging the identification of manufacturers and potentially the implementation of the production.</td>
</tr>
<tr>
<td>36</td>
<td>Manufacturing simplicity</td>
<td>EXCIPIENTS</td>
<td>If the excipients are well known (pharmacopeia), neither costly nor difficult to supply, the MPP intervention would be considered of high value as the implementation would be facilitated. If the excipient is used only in a few medical products or its cost impacts significantly on the cost of goods or the low availability can hinder the supply of the medical product, it would likely result in more difficulties in supplying the excipients or in affecting the product pricing.</td>
</tr>
<tr>
<td>37</td>
<td>Presentation and storage</td>
<td>SHELF-LIFE AND STORAGE CONDITIONS</td>
<td>Higher value of MPP intervention is for products with a shelf-life of at least two years at room temperature. A more moderate value would be for products with a shelf-life between one year (excluded) and two years at non-controlled temperature or storage at controlled temperature (e.g. 2-8°C). Lower value for MPP intervention could be for products with a shelf-life lower than one year (included) or with storage in frozen conditions (e.g. -20°C) as it would likely complexify the product distribution.</td>
</tr>
<tr>
<td>38</td>
<td>Presentation and storage</td>
<td>MEDICAL DEVICE</td>
<td>Tablets, pills, and vials presentations are considered as standard and would be in principle facilitated by an MPP intervention. Pre-filled syringes (PFS) are considered a medium standard. Intranasal medical devices, insulin pens, or patches are considered non-standard as they require specific equipment, access to specific and potentially costly devices and could imply specific regulatory requirements. In such situations, the potential impact of an MPP intervention needs to be evaluated on a case-by-case basis. This classification could be revised based on the deeper impact of the different medical devices and other potential variables.</td>
</tr>
<tr>
<td>CRITERIA FOR PRODUCT'S ASSESSMENT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>N</strong></td>
<td><strong>CRITERIA</strong></td>
<td><strong>SUB-CRITERIA</strong></td>
<td><strong>EXPLANATION OF THE CRITERIA</strong></td>
</tr>
<tr>
<td>39</td>
<td>Regulatory pathway</td>
<td>REGULATORY PATHWAY FOR THE LICENSEES</td>
<td>Probable regulatory pathway for the licensee. Higher rating is attributed to products where the originator product is already approved by SRA/WHO PQ, where the generics have regulatory pathways. Lower rating is attributed to products where the originator is not filed with any regulatory authority, where there is apparently no pathway for the licensee to file their product. Medium rating is attributed to products where the originator has approval in non-SRA countries, but no approval in SRA/WHO PQ. In such cases, potential sub-licensees would need to wait to have the originator product approved with SRA /WHO PQ to file their own product.</td>
</tr>
<tr>
<td>40</td>
<td>Regulatory cost and complexities</td>
<td>COST AND COMPLEXITIES OF REGULATORY FILING</td>
<td>The costs associated with regulatory filing are to be assessed separately here. This includes the cost of development, including possible studies (bioequivalence (BE), pre-clinical, clinical, etc.), cost of reference listed drug (RLD), etc. Simple generic products could be rated as high (since they have less complexities). Complex generic products like long-acting therapeutics, or complex dosage forms could be treated as with moderate complexity. Sometimes, simple generic products might need population studies which might add complexity to BE studies and could be included in this category. Biotherapeutics, which require a biosimilarity package, wherein a battery of preclinical and clinical studies are required, could be categorised as high level of complexity.</td>
</tr>
<tr>
<td>41</td>
<td>Probability of biowaiver / clinical trial waiver</td>
<td>PROBABILITY OF BIOWAIVER /CLINICAL TRIAL WAIVER</td>
<td>This aspect gets assessed in regulatory cost but needs to be understood separately if a biowaiver/clinical trial waiver is possible. High probability of biowaiver is there for oral solids of BCS Class I, or solutions. Moderate probability for biowaiver is where a molecule might have a probability of biowaiver/clinical trial waiver but there could be other studies/justifications required. For biotherapeutics, some less complex molecules with a PD marker might be included in this category. Low probability of biowaiver is applicable to BCS Class II /IV molecules. Complex biotherapeutics like mAbs would also fall in this category.</td>
</tr>
<tr>
<td>N</td>
<td>CRITERIA</td>
<td>SUB-CRITERIA</td>
<td>EXPLANATION OF THE CRITERIA</td>
</tr>
<tr>
<td>----</td>
<td>-----------------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>42</td>
<td>Affordability/availability of the candidate</td>
<td>CANDIDATE-PRODUCT’S AVAILABILITY IN LMICS</td>
<td>Availability of target product in LMICs to assess impact of voluntary licensing and business case.</td>
</tr>
<tr>
<td>43</td>
<td>Affordability/availability of the candidate</td>
<td>CANDIDATE-PRODUCT’S AFFORDABILITY IN LMICS</td>
<td>Affordability of target product in a sample of countries with reference to SoC, to assess impact of voluntary licensing and business case.</td>
</tr>
<tr>
<td>44</td>
<td>Commercial potential for MPP generic manufacturers’ network</td>
<td>COMPANY COMMERCIAL FOOTPRINT</td>
<td>Commercial reach of company across the targeted MPP territories to understand if an in-house access program can reach people in need.</td>
</tr>
<tr>
<td>45</td>
<td>Commercial potential for MPP generic manufacturers’ network</td>
<td>MARKET SIZE</td>
<td>Annual sales of the product globally and in a sample of territories to understand generic business case and impact on originator profit and loss.</td>
</tr>
<tr>
<td>46</td>
<td>Commercial potential for MPP generic manufacturers’ network</td>
<td>EXISTENCE, AVAILABILITY AND PRICE OF ALTERNATIVE OF MARKETED TREATMENTS</td>
<td>To assess need and business case for originators.</td>
</tr>
<tr>
<td>47</td>
<td>Commercial potential for MPP generic manufacturers’ network</td>
<td>EXISTENCE AND AVAILABILITY OF ALTERNATIVE TREATMENTS IN PIPELINE</td>
<td>Existence and availability of alternative therapies in development to focus our priorities and generic interest.</td>
</tr>
<tr>
<td>48</td>
<td>Commercial potential for MPP generic manufacturers’ network</td>
<td>PRODUCT ATTRACTIVENESS FOR THE LICENSEES</td>
<td>Commercial attractiveness in terms of potential sales and volumes (which could be considered as a proxy for generic manufacturers potentially interested in developing the product).</td>
</tr>
<tr>
<td>49</td>
<td>Commercial potential for MPP generic manufacturers’ network</td>
<td>PROCUREMENT</td>
<td>Whether there are any established procurement mechanisms available for this type of product.</td>
</tr>
<tr>
<td>50</td>
<td>Commercial potential for MPP generic manufacturers’ network</td>
<td>COMPETITIVE PRODUCTS (INCLUDING ALREADY EXISTING GENERIC VERSIONS OF THE CANDIDATE AND SAME CLASS PRODUCTS)</td>
<td>Market share according to what is in the pipeline.</td>
</tr>
<tr>
<td>51</td>
<td>Impact</td>
<td>POTENTIAL SAVING FOR PUBLIC HEALTH</td>
<td>Commercial impact that generic manufacturers would create after MPP intervention. Whether MPP would be improving the status quo for patients and governments.</td>
</tr>
</tbody>
</table>
References

HIV

- Unitaid – Global HIV & AIDS statistics – Fact sheet
- Medicines Patent Pool – Press release: MPP announces its Community Advisory Panel (CAP) to support the implementation of the organisation’s new strategy
- Coalition to Accelerate Access to Long-Acting PrEP – Fact sheet

lenacapavir

- Conference on Retroviruses and Opportunistic Infections 2024: Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
- SUNLENCA; U.S. Food & Drug Administration Prescribing Information
- Conference on Retroviruses and Opportunistic Infections 2024: Efficacy and Safety of Weekly Islatravir Plus Lenacapavir in PWH at 24 Weeks: A Phase II Study

cabotegravir & rilpivirine

- CABENUVA; U.S. Food & Drug Administration Prescribing Information
- Conference on Retroviruses and Opportunistic Infections 2024: Randomized trial of Cabotegravir and Rilpivirine Long-acting in Africa (CARES): Week 48 Results
- Conference on Retroviruses and Opportunistic Infections 2024: Long-Acting Injectable CAB/ RPV is Superior to Oral ART in PWH With Adherence Challenges: ACTG A5359
- Conference on Retroviruses and Opportunistic Infections 2024: Phase 1 Study of Cabotegravir Long-Acting Injectable Formulations Supports >4-Monthly Dose Interval

doravirine

- PIFELTRO; U.S. Food & Drug Administration Prescribing Information

islatravir

- Islatravir QW dose in HIV virologically supressed PWH
- Conference on Retroviruses and Opportunistic Infections 2024: Efficacy and Safety of Weekly Islatravir Plus Lenacapavir in PWH at 24 Weeks: A Phase II Study,

monoclonal antibodies for HIV post-natal prophylaxis

- Press Release: IAVI and partners kick-start CELEBRATE study to explore acceptability and feasibility of bnAbs for infant HIV prevention
- CROI 2023: The promise of bnAbs for infant post-natal prophylaxis to end paediatric HIV: the path forward

TB

- quabodepistat
- Otsuka Pharmaceutical Co., Ltd; Corporate website
- A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis - NCT05678688
- PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
- MedsPaL - The Medicines Patents and Licences Database - Quabodepistat

- BTZ-043
- BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA) - NCT04044001
- MedsPaL - The Medicines Patents and Licences Database - BTZ-043

- delpazolid
- PanACEA DEpazolid Dose-finding and COmbinination DEvelopment (DECODE) - NCT04550832
- MedsPaL - The Medicines Patents and Licences Database - Delpazolid

- ganfeborole
- An Early Bactericidal Activity, Safety and Tolerability of GSK3056656 in Subjects With Drug-sensitive Pulmonary Tuberculosis - NCT03557281
- GlaxoSmithKline Pharmaceuticals Ltd; Press release: GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis

- macozinone
- Innovative Medicines for Tuberculosis Foundation
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing - NCT03776500
- Phase 1 Study of PBTZ169 - NCT03056163

- sudapyridine
- Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 (WX-081) - NCT04608925
World Health Organization - Cancer - Key facts

LUNG CANCER


BREAST CANCER

- Vernezio; U.S. Food & Drug Administration Prescribing Information

CHRONIC LYMPHOCYTIC LEUKAEMIA

- KISAQLI; U.S. Food & Drug Administration Prescribing Information

Ribociclib


Herceptin Hylecta


Trastuzumab SQA

- HERCEPTIN MYLECTA; U.S. Food & Drug Administration Prescribing Information

Tagrisso

- MUSICAL; U.S. Food & Drug Administration Prescribing Information

Tagrisso


Osimertinib


Zanubrutinib


Ibrutinib

- IMBRUVICA; U.S. Food & Drug Administration Prescribing Information

Zanubrutinib


Ibrutinib

- IMBRUVICA; U.S. Food & Drug Administration Prescribing Information
PROSTATE CANCER


MULTIPLE CANCER INDICATIONS

- Oral paclitaxel / encequidar

DIABETES

- International Diabetes Federation - Diabetes Atlas 2021
- incretin-based therapies
- World Health Organization – Cardiovascular diseases (CVD) - Key facts
  - cardiovascular fixed-dose combination therapies
  - An application to include fixed dose combinations in the WHO Model List of Essential Medicines for primary and secondary prevention of atherosclerotic cardiovascular diseases in adults
### Abbreviations and acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3TC</td>
<td>lamivudine</td>
</tr>
<tr>
<td>AMR</td>
<td>antimicrobial resistance</td>
</tr>
<tr>
<td>ANDA</td>
<td>abbreviated new drug application</td>
</tr>
<tr>
<td>API</td>
<td>active pharmaceutical ingredient</td>
</tr>
<tr>
<td>ARV</td>
<td>antiretroviral</td>
</tr>
<tr>
<td>BCS</td>
<td>biopharmaceutical classification system</td>
</tr>
<tr>
<td>BE</td>
<td>bioequivalence</td>
</tr>
<tr>
<td>BIC</td>
<td>bictegravir</td>
</tr>
<tr>
<td>bNAb</td>
<td>broadly neutralising antibodies</td>
</tr>
<tr>
<td>BTKi</td>
<td>Bruton’s Tyrosine Kinase Inhibitor</td>
</tr>
<tr>
<td>CAB</td>
<td>cabotegravir</td>
</tr>
<tr>
<td>CAB-LA</td>
<td>cabotegravir long-acting</td>
</tr>
<tr>
<td>CFTR</td>
<td>cystic fibrosis transmembrane conductance regulator</td>
</tr>
<tr>
<td>CADO</td>
<td>Conference on Antiretroviral Drug Optimization</td>
</tr>
<tr>
<td>CAP</td>
<td>community advisory panel</td>
</tr>
<tr>
<td>CDK 4/6</td>
<td>Cyclin-dependent kinase 4 and 6</td>
</tr>
<tr>
<td>CHAI</td>
<td>Clinton Health Access Initiative</td>
</tr>
<tr>
<td>CKD</td>
<td>chronic kidney diseases</td>
</tr>
<tr>
<td>CLHIV</td>
<td>children living with HIV</td>
</tr>
<tr>
<td>CLL</td>
<td>chronic lymphocytic leukemia</td>
</tr>
<tr>
<td>CROI</td>
<td>Conference on Retroviruses and Opportunistic Infections</td>
</tr>
<tr>
<td>CVD</td>
<td>cardiovascular disease</td>
</tr>
<tr>
<td>DALYs</td>
<td>disability-adjusted life years</td>
</tr>
<tr>
<td>DDI</td>
<td>drug-drug interactions</td>
</tr>
<tr>
<td>DOT</td>
<td>directly observed therapy</td>
</tr>
<tr>
<td>DTG</td>
<td>dolutegravir</td>
</tr>
<tr>
<td>EASL</td>
<td>European Association for the Study of the Liver</td>
</tr>
<tr>
<td>EGFR</td>
<td>Epidermal Growth Factor Receptor</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>EML</td>
<td>Essential Medicines List</td>
</tr>
<tr>
<td>ESMO</td>
<td>European Society for Medical Oncology</td>
</tr>
</tbody>
</table>

### EU-M4All

The European Medicines Agency (EMA), in cooperation with the World Health Organization (WHO), can provide scientific opinions on high priority human medicines, including vaccines, that are intended for markets outside of the European Union (EU). The procedure is called EU-Medicines for all or ‘EU-M4all’.

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDC</td>
<td>Fixed dose combination</td>
</tr>
<tr>
<td>GAP-f</td>
<td>Global Accelerator for Paediatric Formulations</td>
</tr>
<tr>
<td>GLP-1 RA</td>
<td>Glucagon-like peptide-1 receptor agonists</td>
</tr>
<tr>
<td>GMP</td>
<td>Good manufacturing practices</td>
</tr>
<tr>
<td>HbS</td>
<td>Sickle haemoglobin</td>
</tr>
<tr>
<td>HBV</td>
<td>Hepatitis B virus</td>
</tr>
<tr>
<td>HCV</td>
<td>Hepatitis C virus</td>
</tr>
<tr>
<td>HDV</td>
<td>Hepatitis Delta Virus</td>
</tr>
<tr>
<td>HER2</td>
<td>human epidermal growth factor receptor 2</td>
</tr>
<tr>
<td>HIC</td>
<td>High-income countries</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HPV</td>
<td>Human papillomavirus</td>
</tr>
<tr>
<td>HR</td>
<td>Hormone Receptor</td>
</tr>
<tr>
<td>HSC</td>
<td>Heat-stable carbetocin</td>
</tr>
<tr>
<td>IAS</td>
<td>International AIDS Society</td>
</tr>
<tr>
<td>ICI</td>
<td>Immune checkpoint inhibitors</td>
</tr>
<tr>
<td>IDF</td>
<td>International Diabetes Federation</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>INSTI</td>
<td>Integrate strand transfer inhibitor</td>
</tr>
<tr>
<td>IP</td>
<td>Intellectual property</td>
</tr>
<tr>
<td>ISL</td>
<td>islatravir</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous</td>
</tr>
<tr>
<td>KRAS</td>
<td>Kirsten rat sarcoma virus</td>
</tr>
<tr>
<td>LENV</td>
<td>lenacapavir</td>
</tr>
<tr>
<td>LA</td>
<td>long-acting</td>
</tr>
<tr>
<td>LMICs</td>
<td>Low- and middle-income countries</td>
</tr>
<tr>
<td>LRTI</td>
<td>Lower respiratory tract infections</td>
</tr>
<tr>
<td>MAGPH</td>
<td>Marketing Authorisation for Global Health Products</td>
</tr>
<tr>
<td>-------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>mAbs</td>
<td>Monoclonal antibodies</td>
</tr>
<tr>
<td>MDR-TB</td>
<td>Multi-drug-resistant tuberculosis</td>
</tr>
<tr>
<td>MPP</td>
<td>Medicines Patent Pool</td>
</tr>
<tr>
<td>NNRTI</td>
<td>Non-Nucleoside Reverse Transcriptase Inhibitor</td>
</tr>
<tr>
<td>NCD</td>
<td>Non-communicable diseases</td>
</tr>
<tr>
<td>NMPA</td>
<td>China National Medical Products Administration</td>
</tr>
<tr>
<td>NSCLC</td>
<td>Non Small Cell Lung Cancer</td>
</tr>
<tr>
<td>OEB</td>
<td>Occupational Exposure Bands</td>
</tr>
<tr>
<td>OEL</td>
<td>Occupational Exposure Limits</td>
</tr>
<tr>
<td>PADO</td>
<td>Paediatric Antiretroviral Drug Optimization</td>
</tr>
<tr>
<td>PAN-TB</td>
<td>Project to Accelerate New Treatments for Tuberculosis</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase Chain Reaction</td>
</tr>
<tr>
<td>PD</td>
<td>Pharmacodynamics</td>
</tr>
<tr>
<td>PD-1</td>
<td>Programmed cell Death 1</td>
</tr>
<tr>
<td>PD-L1</td>
<td>Programmed cell Death Ligand 1</td>
</tr>
<tr>
<td>PEPFAR</td>
<td>President’s Emergency Plan for AIDS Relief</td>
</tr>
<tr>
<td>PK</td>
<td>Pharmacokinetics</td>
</tr>
<tr>
<td>PLHCV</td>
<td>People living with HCV</td>
</tr>
<tr>
<td>PLHIV</td>
<td>People living with HIV</td>
</tr>
<tr>
<td>PNP</td>
<td>Post-natal prophylaxis</td>
</tr>
<tr>
<td>PPH</td>
<td>Post-partum haemorrhage</td>
</tr>
<tr>
<td>PrEP</td>
<td>Pre-Exposure Prophylaxis</td>
</tr>
<tr>
<td>PSA</td>
<td>Prostate-Specific Antigen</td>
</tr>
<tr>
<td>PWID</td>
<td>People who inject drugs</td>
</tr>
<tr>
<td>Q1</td>
<td>qualitative sameness</td>
</tr>
<tr>
<td>Q2</td>
<td>quantitative sameness</td>
</tr>
<tr>
<td>RMNCH</td>
<td>Reproductive, maternal, newborn and child health</td>
</tr>
<tr>
<td>RPV</td>
<td>Rilpivirine</td>
</tr>
<tr>
<td>RR-TB</td>
<td>Rifampicin-resistant tuberculosis</td>
</tr>
<tr>
<td>RSV</td>
<td>Respiratory Syncytial Virus</td>
</tr>
<tr>
<td>SAP</td>
<td>Scientific Advisory Panel</td>
</tr>
<tr>
<td>SCD</td>
<td>Sickle Cell Disease</td>
</tr>
<tr>
<td>SDC</td>
<td>Swiss Agency for Development Cooperation</td>
</tr>
<tr>
<td>SoC</td>
<td>Standard of care</td>
</tr>
<tr>
<td>SQ</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>SRA</td>
<td>Stringent Regulatory Authorities</td>
</tr>
<tr>
<td>SSA</td>
<td>sub-Saharan Africa</td>
</tr>
<tr>
<td>STI</td>
<td>sexually transmitted infections</td>
</tr>
<tr>
<td>Swissmedic</td>
<td>Swissmedic procedure for scientific advice and Marketing Authorisation for Global Health Products</td>
</tr>
<tr>
<td>T1DM</td>
<td>Type 1 Diabetes</td>
</tr>
<tr>
<td>T2DM</td>
<td>Type 2 Diabetes</td>
</tr>
<tr>
<td>TAF</td>
<td>tenofovir alafenamide</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>TDF</td>
<td>tenofovir disoproxil fumarate</td>
</tr>
<tr>
<td>Global Fund</td>
<td>The Global Fund to Fight AIDS, Tuberculosis and Malaria</td>
</tr>
<tr>
<td>TLD</td>
<td>tenofovir/lamivudine/dolutegravir</td>
</tr>
<tr>
<td>TKI</td>
<td>tyrosine kinase inhibitor</td>
</tr>
<tr>
<td>UHC</td>
<td>Universal Health Coverage</td>
</tr>
<tr>
<td>UK</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>UNAIDS</td>
<td>Joint United Nations Programme on HIV/AIDS</td>
</tr>
<tr>
<td>USD</td>
<td>United States Dollar</td>
</tr>
<tr>
<td>USFDA</td>
<td>The United States Food and Drug Administration</td>
</tr>
<tr>
<td>Para III</td>
<td>Paragraph III Certification means a certification that a generic applicant seeks FDA approval of its abbreviated new drug application (ANDA) as of the date a patent listed in the Orange Book for a relevant new drug application (NDA) expires.</td>
</tr>
<tr>
<td>UTI</td>
<td>Urinary tract infection</td>
</tr>
<tr>
<td>UUG</td>
<td>Uncomplicated urogenital gonorrhoea</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WHO-PQ</td>
<td>WHO Pre-Qualification of Medicines Programme</td>
</tr>
</tbody>
</table>
Acknowledgments

MPP would like to acknowledge the valuable support of the experts of its Scientific and Community Advisory Panels (SAP & CAP) in informing the prioritisation exercise.

MPP was founded by:

MPP’s activities are undertaken with the financial support of: